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Chapter 1
– Introduction –
Abstract: The aim of ALTHERAS (ALzheimer THERApeutic System) is the
development of a drug delivery system to enable improvement in the individual
medication of people suffering from Alzheimer’s disease. Transdermal systems
are particularly attractive as they represent a non-invasive and self regulated
treatment. The goal is to create a system in which the drug is immobilized and
released by a light induced cleavage. As a consequence, the project involves a
multi-disciplinary approach, using suitable chemistry combined with pharma-
ceutical engineering, physics and nanotechnologies. The main objectives are the
manufacturing of a pre-prototype through the identification of basic specifica-
tions and the obtaining of the proof of concept.
Introduction ALTHERAS
1.1 ALTHERAS: Presentation of the topic
This project aims in the creation of a transdermal therapeutic system (TTS)
making possible on the same time automation and polymedication. Herein, the
creation of the ALTHERAS transdermal therapeutic system (ATTS) is sug-
gested.
The core of the project is the reversible immobilisation of a medication (drug,
excipient, etc.) on a substrate and its release using a physical stimulus. The
programmed control of the stimulus emission guarantees an automatic control
of the administration, thus reducing the risk of patients forgetting. On the
other hand, it complements favourably the use of drug combinations. In this
project a new therapeutic system using the transdermal pathway is designed to
independently control in time and in dose the release of drugs.
The ATTS involves the development of adapted materials, an electronic
control unit implemented in the system, a source of stimulus to induce the
release and a wireless data transfer module for individual programming by the
doctor, clinician or by the patient. In practice, the ATTS is divided into three
parts which are presented in figure 1.1.
A
B
Electronic support
Adhesive support
Medication suppor
Release stimulus
Immobilized medication
Released medication
Figure 1.1: Principle of the ATTS
A: System OFF ; B: System ON
The electronic support (eS): which comports an energy supply unit, a progr-
ammable memory and a stimulus emitter ;
The medication support (mS): on which the medication is immobilized ;
The adhesive support (aS): which keeps the full system in contact with the
skin.
1.2 Context
The use of smart apparatus able to manage and anticipate therapeutic needs of
a patient is impressively growing [1]. On the same time, due to a better under-
standing of multi-factorial diseases, the discovery of drug cocktails is opening
the way to individualized therapeutic treatments as specific drug interactions
may be tuned depending on the patient.
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By identifying drug combinations and associated synergistic effects, the phar-
maceutical industry is looking to develop more efficient therapies to reduce doses
and side effects. Moreover, the controlled release of such therapeutic molecules
would implement the success of the therapy.
1.2.1 Chronic diseases
1.2.1.1 General remarks
Chronic diseases are characterised by a long therm and evolutive sickness, almost
always associated with complications and invalidity. They represent the major
cause of death and disability worldwide as they are considered to be responsible
for almost 60% of all deaths and 43% of the world diseases. Furthermore, their
impact in a long term of 10 years will rise the number of death to 73%. These
pathologies include different categories:
Long-term mental disorders including depressive disorder, schizophrenia,
Alzheimer’s or Parkinson’s disease, chronic pain ;
Rare diseases such as mucoviscidosis, drepanocytosis or myopathy ;
Persistent communicable diseases with HIV/AIDS or hepatitis ;
Others: chronic kidney disease, chronic bronchitis, asthma, cardiovascular dis-
eases, cancers, diabetes, and multiple sclerosis.
The compliance refers to the following of treatment recommendations. Bad
compliance accentuates the symptoms and can lead to grave consequences in-
cluding over-dosage, sub-dosage, bad combinations or incorrect administration
time. This phenomenon is particularly common in case of elder people as they
tend to live isolated, take multiple medicines and have decreased dexterity.
A World Health Organization (WHO) study estimates that in developed
countries only 50% of people suffering from chronic diseases follow treatment
recommendations. The main identified obstacles include the complexity of mod-
ern medications, a non-understanding of the treatment, the side effects and the
cost of medicines.
1.2.1.2 Case of Alzheimer’s disease
Alzheimer’s disease (AD) is a multifactorial degenerative disease which leads to
a decline of cognitive capacities and memory [2]. The diagnosis remains difficult
but symptoms are generally observed before the age of 60 years old. On the
same time, the incidence increases significantly with age and represents the most
frequent form of dementia in old people with almost 65% of cases.
Dementia generally includes a decrease of mental faculties, however AD is
different as it evolves gradually and, in the first stage, seems to affect mainly the
short term memory. It is a very complex and multi-factorial disease that involves
a large amount of biological mechanisms and physiological functions in the brain.
This could explain why it is so difficult to identify efficient medications despite
of years of academic and pharmaceutical research.
3
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The pharmaceutical market is currently dominated by 4 molecules (Figure
1.2) even if others are in pipelines. Among these drugs, three (Figures 1.2a,
1.2b and 1.2c) are anticholinesterase inhibitors (AchEI), meaning that they in-
hibits the activity of enzymes involved in acetylcholine degradation. The 4th
molecule (Figure 1.2d) is a N -methyl-D-aspartate (NMDA) receptor antagonist
as it inhibits the action of the NMDA receptor.
O
N
O
O
(a) Donepezil
O
N
O
OH
(b) Galantamine
O
O
N
N
H
(c) Rivastigmine
NH2
(d) Memantine
Figure 1.2: Common molecules used for AD treatment
A recent and innovative strategy to treat AD consists in the development of
drug combinations, acting simultaneously on different targeted sites or having
synergistic effects. The goal is to increase clinical efficiency while reducing side
effects. However, the major drawback when applying multiple drugs resides
in the different pharmacokinetics of the drugs. As a consequence, the main
challenge is to bring the proper amount of drug at the right place and right
moment.
1.2.2 Drug delivery
1.2.2.1 General remarks
The drug delivery refers to the administering of a pharmaceutical compound
to a patient. The pharmacokinetic properties such as absorption, distribution,
metabolism and excretion (ADME) of active compounds are necessarily influ-
enced by the route of administration.
The Food and Drug Administration (FDA) currently distinguishes more than
100 distinct ways to administer a drug. They can be divided into 4 main forms:
Topical delivery: epicutaneous, inhalation, enema, eyes drops, ears drops, in-
tranasal, etc. ;
Enteral delivery: mouth or orally, gastric feeding, duodenal feeding tube, rec-
tally, suppository, enema, etc. ;
4
ALTHERAS Introduction
Parenteral delivery: injection, infusion, intravenous, intraarterial, intramus-
cular, intracardiac, subcutaneous, intraosseous infusion, intradermal, in-
traperitoneal, transdermal, transmucosal, inhalational, etc. ;
Others: intraperitoneal, e.g. peritoneal dialysis, epidural, intrathecal.
Each of these formulations presents advantages and disadvantages, depend-
ing on the drug characteristics (molecular size, charge, etc.), on the patient
(compliance, etc.) and on the type of disease. Common delivery systems suffer
from restrictions such as burst release so the maintenance of blood therapeutic
doses is challenging. Furthermore several medications such as peptides, pro-
teins, antibodies, and gene based drugs cannot be delivered without a special
attention from enzymatic or metabolic degradation.
Among drug delivery formulations, TTS are used for the administration of
drug by its diffusion through the skin. They represent an appealing and non-
invasive tool known to minimize the limitations allied with oral or parenteral
administration as the medication reaches directly the blood stream. For these
reasons, the transdermal pathway has become a well accepted drug delivery
method.
1.2.2.2 Transdermal therapeutic systems
The historical use of plasters as medical devices can be tracked back up to
the Egyptians which have developed formulations for cosmetic and therapeutic
applications [3,4]. In recent years the knowledge of molecular and physical mech-
anisms involved in dermal release have been deeper understood, leading to the
establishment of new TTS.
Modern TTS are used to deliver a specific dose of drug through the skin with
a controlled kinetic. They implement traditional treatments, limited by poor
oral bioavailability and severe side effects, and represents the most successful
non-oral systemic drug delivery system [5].
The worldwide field of transdermal therapies is a fast growing market, es-
timated to two billion US dollars. By using TTS, the delivery of drugs having
short half-lives presents better plasma profile and avoids the first-pass metabolism
effect for drugs with poor oral bioavailability. In addition, they are a convenient
delivery method with the potential of dose tuning by the patient [6].
TTS provide an adequate drug release from the formulation and at the same
time allow good amount of drug to overcome the skin barrier, preventing unspe-
cific cutaneous rush and drug inactivation [7]. They are formulated in different
forms which present negative aspects such as skin irritation, manufacturing
costs and aesthetic appearance [8,9,10]. Despite these features, they present the
advantage to be non-invasive, easy to use and to successfully reduce side effects
associated with oral administration [11].
Moreover, they can be used in situations requiring minimal patient coop-
eration [9]. Finally, in case of an accidental overdose, an effective disruption of
administration is possible [12] by simply removing the support from the skin.
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1.2.2.3 Transdermal patches
Among the TTS, the transdermal patch (TP) is an interesting alternative as it
combines the advantages of classical TTS with an easy to use support. The first
commercial TP, Transderm Scop® (scopolamine), was approved by the FDA
in the 70’s for sea sickness [1] and signed the beginning of acceptance of this
method for modern commercial drug products [13].
From now, many TP are approved such as Trandate® (methylphenidate) for
the treatment of attention deficit and hyperactivity disorder, Neupro® (rotigo-
tine) for Parkinson’s disease, Emsam® (selegiline) for depression and Durogesic®
(fentanyl) for pain therapy [12]. In July 2007 the Exelon® patch (rivastigmine)
was approved to treat moderate AD. This device constitutes an innovation in
this therapy and in these days another TP using donepezil is under develop-
ment [12,14].
The design of a TP can be divided into 4 traditional architectures which are
reported in figure 1.3 [14]. Some common features are present in each one, such
as a backing layer and an adhesive that assures a good contact with the skin.
Before applying a TP, a peelable layer is removed to expose the adhesive to the
skin. This adhesive layer is placed on the skin applying a little pressure on the
backing layer to make sure the patch is firmly in contact with the skin [15].
The simplest structure consists in a single layer “drug in adhesive” patch
(Figure 1.3a). In this case, drug and potential excipient are directly dispersed
into an adhesive matrix and the release depends only on the diffusion across
the skin [14]. The multi layered version (Figure 1.3c) is based on the same
principle. However, this one has two or more distinct adhesive layers separated
by a membrane designed to modify the release rate.
(a) Single layer
(b) Drug reservoir
(c) Multi layer
(d) Drug matrix
Backing film
Adhesive
Membrane
Drug
Peelable layer
Figure 1.3: TP common structures
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The “drug reservoir in adhesive” (Figure 1.3b) consists in the inclusion of a
drug/excipient solution separated from the adhesive by a membrane. Finally,
the last type of TP (Figure 1.3d) is an inclusion of a semi-solid drug/excipi-
ent matrix surrounded by the adhesive which forms a concentric configuration
around this matrix.
1.2.2.4 Limitations of current drug delivery systems
1.2.2.4.a Polytherapies and drug combinations
Polytherapy consists in multiple medications treatments. Due to different ADME,
drug-drug interactions and higher cost, the development of this kind of treat-
ment is problematic. Other problems associated with polymedication include
potential side effects induced by drug combinations and, in case of complicate
polytherapies, a significant decrease of the compliance.
Even with an adapted posology, treatments requiring the taking of several
drugs remain problematic. Three different cases can be distinguished:
No interaction between drugs: they act on different sites for different patholo-
gies or not but with different mechanisms ;
Correlation of effects: one drug limits the side effects of the other one ;
Synergistic effects: the drugs combinations magnify the individual effects of
the two molecules.
However, the precise control of multiple release from a single support is
a new burgeoning field that presents challenges. This could explain current
developments of drug delivery technologies.
1.2.2.4.b Personalized medicine
With the recent identification of drug combinations, a new parameter was intro-
duced in the administration of drugs making the medication more complex. For
pharmaceutical industries, even if it offers a potential market to personalized
therapies, production problems limits its expansion. Indeed, customized hand-
made galenic prescriptions can sometime be produced by the pharmacist, but
the common way to personalize a treatment remains the doctor prescription.
1.3 State of the art
1.3.1 The skin
The skin represents the largest and most easily accessible organ of the body with
an average surface of approximately 2 m2 [16]. It provides an efficient protec-
tion against environmental aggressions such as temperature changes, chemicals
or pathogens. These features render the skin a strong barrier which hampers
transdermal drug delivery [5,17]. This biological membrane consists of a multi-
layer of biological tissues having a complex organization with a wider variety of
cell types than the brain.
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The three main layers are the epidermis, the dermis and the hypodermis
(Figure 1.4) [17]. The epidermis is composed out of 7 different layers. The most
superficial, the stratum corneum (SC), or non viable epidermis, is responsible
of drug absorption limitations.
Figure 1.4: Anatomy of the skin
1.3.2 Drug adsorption through skin
SC possesses an average thickness from 10 to 20 µm. It consists of approximately
15 to 25 layers of cornified cells, the corneocytes, anchored in a mortar of highly
organized intercellular lipids (Figure 1.5) [18]. Once applied on the skin, a drug
either penetrates via transcellular route, alternately through the corneocytes
and the lipid layers, or using intercellular routes along the tortuous pathways
made by the lipid layers. A third minor way is also present, the appendageal
route, in which the passage happens via sweat glands or follicular ducts [18].
Even if the intercellular route is considered as the most important transder-
mal absorption pathway for small substances [5], the corneocyte arrangement on
the lipid matrix provides a highly tortuous diffusion pathway rendering the SC
1000 times less permeable to water compared to other biological membranes.
This makes the total length of the entire pathway impressively long, around
500 µm, which is higher than the average of the SC thickness.
As a consequence, the transdermal absorption requires drugs having proper
characteristics which allow it to cross the SC or an appropriate carrier able
to deliver the drug [13,19]. Ideally, the molecular weight must be appropriate
to facilitate the drug diffusion through the lipid bilayer but the permeation
through the skin also depends on the ionization degree of the active molecule
at physiological pH [19,20].
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Figure 1.5: “Brick and Mortar” model of the skin organization
The SC is a selective barrier [17] having an important diffusional resistance
due to complex interactions between lipid and protein components. As a matter
of fact, the transdermal delivery of a large amount of drug remains problematic.
Thus, approximately 10 mg of active can be daily delivered if the permeation is
not enhanced [5]. In the last decade, researchers have been focused on develop-
ing new methods to enhance drug permeation across the skin. These methods
can be separated in chemical, otherwise called passive, and physical, or active
methods [9,17]. Furthermore, interesting combinations coupling physical/phys-
ical, chemical/physical methods exist and are well documented [21], as well as
chemical/chemical methods [16].
1.3.2.1 Chemical or passive methods
Chemical permeation enhancers are substances able to promote the drug ab-
sorption through the skin by temporarily altering its permeability. Ideally, in-
volved chemicals are non-toxic, non irritating and compatible with the drug [22].
According to the lipid-protein-partitioning (LPP) theory [7,23], which describes
interactions between penetration enhancers and the SC, the three main mecha-
nisms of enhancement are:
• Interactions with the intercellular lipids ;
• Interactions with the intracellular keratin ;
• Penetration of high amounts of enhancers resulting in an improved dis-
solving capacity of the barrier for drug.
Widely used classical enhancers [24] include molecules such as alcohols [25],
acids amines and amides [4,26], esters, surfactants, terpenes, terpenoids and es-
sential oils [11,27], sulfoxides [22,28], lipids and miscellaneous such as cyclodex-
trins [23,29], enzymes [22], drug mixtures [30] or simply water [31].
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1.3.2.2 Physical or active methods
In addition to passive enhancement, the rates of transdermal transport can be
increased using physical enhancement methods. These type of systems are able
to increase the drug flux by either altering the skin barrier or providing driving
force to the drug [1,17]. Recent advances in engineering and computing led to
the production of small and powerful active TTS.
Examples include sonophoresis, using ultrasounds to induce SC lipid dis-
ruption [5,10,32] ; electroporation, creating temporary pores by short exposure to
high voltage current [33,34] ; local thermal treatment, dilating skin pores [35] ; skin
disruption by micro-needles or blades [18,36,37] ; high velocity particles propul-
sion [18] ; laser pressure wave [38] and iontophoresis, forcing drugs to diffuse by
repulsion from an electrode [18,39].
1.3.2.3 Nanotechnology case
Over the past few decades, drug delivery systems have been improved by nan-
otechnologies with the use of drug nanocarriers [40,41,42] for diagnostics [43] or vac-
cines [44]. They are designed to prevent drug degradation [45] and uncontrolled
interactions with unspecific targets. However, due to their features many risks
remain unknown.
For this reason biocompatibility and biodegradability of the constituting
materials are important requirements that have to be considered. Thus, only
a limited number of biodegradable polymeric nanoparticles (NP) [46], solid lipid
nanoparticles (SLN) [47,48], and nano-structured lipid carriers (NLC) have been
studied in drug delivery systems. One of the most common polymer used nowa-
days for drug delivery is the poly (lactic-co-glycolic acid) (PLGA), which is
biocompatible and biodegradable [10,49,50,51,52].
1.4 ALTHERAS: A technological breakthrough
1.4.1 Identification of main specifications
In order to face the disadvantages of multi therapies, two needs are identified:
Tool for polytherapy: Automatic management of multi drug release ;
Tool for chronotherapy: Automatic control of the time of administration.
Since ADME plays a major role in a therapy, the time control of drug release
makes it possible to adapt a treatment to the patient needs. A tool allowing the
delivery of a medicine at the right moment, even during sleeping time, would be
a significant improvement. As a consequence, the drug delivery system designed
can be programmed to release a molecule at specific times.
Ideally, the delivery device would be applied to the patient after its program-
ming by the doctor. Moreover, the tool proposed is a real opportunity to allow
the delivery of complex treatments and interactions do not have to be taken
into account by the patient.
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1.4.2 Proposals
The transdermal delivery remains one of the most convenient way to administer
a drug for chronic disease. Simplicity of use, economical impact and personal
tuning are the most evident achievement of this administration method. The
main advantage of the ATTS is the possibility to tune the drug release. There-
fore, the principal idea is the immobilization of pharmaceutical compounds on
a support and the use of an external stimulus to release the molecules according
to ADME. Once the drug is released, its absorption happens as for a normal
TTS by simple diffusion of the molecule through the skin.
In reply to specifications, detailed technical proposals based on scientific
literature, books, patents, etc. were studied. These proposals concern the
chemistry and physics involved in the production, but also pharmaceutical en-
gineering in close relation with electronics and programming.
1.4.2.1 Release stimulus
Different physical stimuli are able to trigger the release such as temperature
changes, electric potential or electromagnetic signals. However, each method
presents important disadvantages that can limit their potential uses:
Temperature change can induce the modification of a support, causing the
release of entrapped molecule. However this option is limited to significant
temperature changes leading to a possible degradation of the drug and
risks for the patient. Moreover, the thermodegradation of the support
does not fit the requirements ;
Electric potential to force the molecule migration, is already used today in
iontopheretic TTS. An important issue in this approach is that the drug
molecules have to be charged, which limits the number of suitable drugs.
Moreover, the energy consumption remains an important parameter ;
Electromagnetic impulse is an interesting way to trigger a drug delivery
without any of the disadvantages previously described. Using this method,
the release of an immobilized medication would be induced by energy
conversion of the electromagnetic signal. An optical approach, using light
wavelengths, offers a clear advantage regarding its acceptance by the skin
and the already existing embedded systems comporting LED technology.
1.4.2.2 The medication support
1.4.2.2.a Geometric considerations
According to the Richardson effect [53] applied to 3D structures, the surface to
volume ratio of an object is inversely proportional to its size. For this reason,
in order to reach high drug loading in a reduced volume, the covalent immobi-
lization of the drug on small entities which are then embedded into a polymer
matrix was considered. This method allows a high loading performance while
reducing the complexity of the process by separating the drug immobilization
from the embedding process.
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Different possibilities emerge from this statement such as the immobilization
on foil, micro-fibers, micro-particles or on a porous structure (Figure 1.6).
(a) (b) (c) (d)
Figure 1.6: Possible designs for medication immobilization on support
General (up) and detailed (down) view.
(a) Foil support ; (b) Micro-fibre support ;
(c) Micro-particle support in polymer matrix ; (d) Porous structure matrix as
support
As shown in design 1.6a, 1.6b and 1.6c, the use of a polymer matrix to fix
the drug supports necessarily induces limitations for the diffusion of the active
molecules. Indeed, in that case the polymer also serves as supporting structure
for the TP, which means the use of a polymer having high viscosity η.
However, according to the Stokes-Einstein equation 1.1 the diffusion constant
(D) for a molecule decreases with an increase of the media viscosity:
D = Kb T6 pi η r (1.1)
In a porous structure as in figure 1.6d, the scaffold plays the role of the
supporting structure and immobilization support. In that case the drug diffusion
is assured by a diffusion media (dM) which can be a liquid or a gel with low
viscosity. This dM fills the porous structure and allows a fast diffusion. In this
study, highly porous structures appeared as the best candidates for the design of
the ATTS. In this manner, properties and porosity of the support are selectively
tuned to control the release.
1.4.2.2.b Porous polymeric materials in TTS
The main challenge when producing a new TP lies in the design of a matrix.
This is followed by the optimization of the drug loading, not only in terms
of release properties, but also with respect to its physico-chemical properties,
compatibility and stability with other components as well as with the skin [54].
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General requirements of the polymer matrices are:
• Properties allowing fast diffusion of the drug ;
• Stability ;
• Easy manufacturing and fabrication ;
• Biocompatibility.
Common matrix materials include natural polymers such as cellulose deriva-
tives [11,27,55], chitosan [56,57] or synthetic ones as povidone also commonly called
polyvinylpyrrolidone (PVP) [6,11,58]. Hydrogel type porous systems in transder-
mal delivery [59,60] are advantageous as they overcome side effects such as skin
irritation or problems associated with classical polymer matrix TTS by using a
water based solution as dM. Different production methods and materials have
been studied [61,62,63,64,65,66].
This study focused on the establishment of a chitosan porous matrix (ChipM)
for controlled release. Chitosan scaffolds are particularly interesting as the final
material is transparent, flexible [67] and allows an easy surface modification. Fi-
nally chitosan is approved by the FDA for drug delivery [68] and presents good
characteristics regarding its biocompatibility [67] and antimicrobial activity [69].
1.5 Aim and outline of the thesis
Due to their ability to relieve the patient of treatment management by following
pre-established care plans, the intelligent technologies are an interesting way to
improve cares and compliance. On the same time, the introduction of mobile
technology able to communicate recommendations and medication adjustments
depending on the situation demands in real time is another possibility.
The aim of this work is the design of a medication support in which an active
molecule is bound covalently to a support through a photocleavable linker. The
active molecule is then released upon irradiation of the support by near UV
light (λ = 365 nm). This type of delivery system is already described [70], but
despite the complexity of the system, technical explanations suffer from a lack
of data, rendering the production difficult. According to the claims of this
patent, a process for the production of the ATTS was developed. The design
comprehends:
A highly functionalized mS for drug immobilization, stable when surface
modification is performed ;
A photolinker activated at λ = 365 nm and able to release proper amounts
of medication without toxic residues ;
A suitable chemistry for mS surface modification, based on simple, high
yield and established reactions ;
An in vitro study proving that the drug model is released trough human skin
epidermis ;
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A design proposal which renders easy the programming of the system and
leading to almost infinite possibilities of drug cocktails.
The first part of the project consists in the identification of main speci-
fications. This work takes into account different points of view such as the
technologies for the production of the pre-prototype, the concordance with its
use in the field of drug delivery and the economical point of view. The final
step is the obtaining of the proof of concept, which means the establishment of
technical feasibility for production and the proof of a significant drug release
from a pre-prototype. The optimization process and are not part of this work.
In Chapter 2 the straightforward high yield synthesis and purification of
a model photolinker is described and shows an interesting potential for scale
up. Chapter 3 details the process for the production of highly homogeneous
ChipM. The assembling of a dedicated apparatus for the production of the
porous material, the porous matrix producer (POMAP), improved considerably
the maintaining of the material characteristics. A thermodynamic study based
on finite element method (FEM) is proposed to describe the production process.
The structure of the obtained material is finally investigated.
In Chapter 4 the surface modification of the porous matrices, first with the
photolinker and then with the drug model, is presented. A procedure is sug-
gested to obtain homogeneous surface attachment to the porous structure. On
the same time, a quantitative study of the coupling capacity is made and the re-
sults are compared to the theoretical loading capacity of the matrix. In Chapter
5 the release of the model drug from the photosensitive drug loaded matrix is
investigated in-vitro using human skin epidermis. The full system is subjected
to UV light and a quantitative study is made to determine the drug release
and diffusion through the epidermis. Furthermore, a mathematical model is
suggested to describe the complex “release and diffusion” of the drug.
Finally, the Chapter 6 concerns the possibilities of use of the system, includ-
ing the design and the programming of the system.
A nomenclature is also proposed in Appendix C to identify the surface mod-
ification and all the parameters involved for the obtaining of each drug loaded
matrices.
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Chapter 2
Design of a photolinker for
UV controlled release
Abstract: Herein is presented a straightforward approach for the complete syn-
thesis of a photolinker used in drug photorelease. This o-nitrobenzyl derivate,
known as the 4-(4-(1-hydroxyethyl)-2-methoxy-5-nitrophenoxy)butanoic acid,
was designed to allow at the same time an easy and stable coupling on a poly-
mer support through an amide bound and a simple photosensitive covalent
attachment of the drug to another part of the molecule. The full synthesis is
described in depth and the possibility of gram scale-up using only high yield
reactions and purification methods based on recrystallization is investigated.
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2.1 General remarks
Photochemistry includes reactions induced by light absorption. Thus the radi-
ant energy is converted to another form of energy such as heat that can imply
a change of the electron state. In that case it is called photo-excitation and
this light assisted electronic transition helps to reduce the activation energy of
a reaction.
One of the most important photochemical reactions is the photosynthesis,
occurring in plants, and using solar energy to convert carbon dioxide and water
into glucose and oxygen. In the laboratory, photosensitive moieties are mainly
used as protecting groups or to initiate coupling reactions. Common photochem-
ical reactions include electrocyclic reactions, photoisomerizations and Norrish
based reactions [1].
Photochemical reactions are very attractive processes and very good general
reviews have been published in this field [1,2]. Many different photo-sensible moi-
eties are already used depending on the activation wavelength, the mechanism
or the solvent [1]. Photolytic cleavage of a chemical bond is, by essence, the
consequence of photon absorption by a molecule.
The most popular photolabile group, either in liquid or solid phase, is the 6-
nitroveratryloxycarbonyl group also called NVOC [3] and its derivatives (Figure
2.1). The original study was based on the NVOC-derived carbamates of amino
acids. Two methoxy groups were then introduced to increase the absorbance at
longer wavelengths.
R1
R2
X
R3NO2
X = OH or NH2
Figure 2.1: General chemical structure of NVOC
The NVOC photocleavage relies on the photochemically-induced photoiso-
merisation of o-nitrobenzyl derivatives into o-nitrosobenzaldehyde [4]. Among all
its possible photodegradation pathways, hydrogen subtraction in the γ-position
is quite common and was identified very early by Norrish [5]. As a consequence,
this process is now described, for carbonyl compounds, as a Norrish-type II re-
action. This group of chemicals were also used for the protection of the hydroxy
groups in carbohydrates, which was introduced in the 70’s [3] with a first use in
solid phase synthesis in 1973 [6].
Among NVOC derivatives, the α-methyl-6-nitroveratryl based [7] photolinker
is the most studied even if β-substitutions are sometimes preferred [2,8]. Never-
theless, for this last one the cleavage mechanism is different [8,9].
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The mechanism of photorelease from nitrobenzyl ether derivates has been
already described in the literature [4,10,11] (Figure 2.2). While submitted to UV
light (λ = 365 nm) a pale yellow solution of α-methyl-6-nitroveratryl in DMSO
becomes brownish and water release is observed by NMR.
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N
O	 O
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R1
R2
OR
⊕
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O	 OH
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N
O
+ ROH
+H
⊕
Figure 2.2: Mechanism of ether photorelease from an o-nitrobenzyl ether
O-nitrobenzyl derivates photocleavage kinetic in solution has been well re-
ported in the literature [4,21,32] depending of the solvent [21], the pH [23], the power
of the UV light and the wavelength [21]. As an example it is known that, in so-
lution, α-methyl-6-nitroveratryl has superior and faster cleavage rate in aprotic
than in protic solvents [17,22].
On the same time it is clearly established that the release capacities of that
category of photolinker is influenced by substituents R1 and R2 [15] (Figure 2.2).
However, when coupled to a solid support news factors appear compared to those
in solution such as light scattering, shadowing effects of the support, stirring,
etc. and important differences have already been observed between cleavage in
solution or from solid support, < 1 min to 1-1.5 h respectively [17], and a limit
of 95% release is evoked without known explanation [17].
Many different groups have been studied for the release from o-nitrobenzyl
derivatives and are listed in table 2.1.
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Structure
Released
molecule Ref.
R1
R2
O
O
X
R5
R4
R3NO2
X = O (R4 = ∅)
X = N (R4 = H)
X = N (R4 = alkyl chain)
Alcohol
Primary amine
Secondary amine
[13]
[15]
[17]
R1
R2
X
R4
O
R5
R3NO2
X = O (R4 = ∅)
X = N (R4 = H)
X = N (R4 = alkyl chain)
Carboxylic acid
Primary amine
Secondary amine
[20]
[22]
R1
R2
X
S
O
O
R4R
3NO2
X = O (R4 = ∅)
X = NH (R4 = alkyl chain)
Sulfonic acid
Sulfonamide
[23]
[24]
R1
R2
X
P
O
R4
O
R5R
3NO2
R4 = H
R4 = alkyl chain
Phosphoester
Phosphodiester
[2]
[4]
[10]
[23]
R1
R2
O R5
R4
O
R3
NO2
R4 = H
R4 = alkyl chain
Aldehyde
Ketone
[25]
Table 2.1: Potential release from NVOC group
2.2 Strategy
For drug controlled release, the strategy of this study is based on the photodegra-
dation of a covalent bond between a polymer scaffold and a drug molecule
preventing any modification of either the scaffold characteristics [26] or of the
drug. The approach consists on a Norrish type II reaction [5] with the use of an
o-nitrobenzyl derivate photolinker [1] to couple the drug to the polymer [27].
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The photosensitive moiety of the photolinker is also of importance for the
diversity of drug release to anticipate different bonds between drug and linker
so a hydroxy group is an optimal candidate [15].
Moreover, the presence of a γ-methyl on the benzylic carbon limits the for-
mation of reactive nitroso-aldehyde upon photolysis.
Among the existing o-nitrobenzyl derivatives, two molecules were selected
as photolinker model for the production of the ATTS. Their full synthesis are
well described in the literature using only accessible raw materials and high
yield reactions. Moreover, the purification consists only in recrystallizations,
allowing an easy scale-up.
The first photolinker model of this study, called PL1, is the 4-(4-(1-amino-
ethyl)-2-methoxy-5-nitrophenoxy) butanoic acid (CAS: 162827-97-6). However,
in order to avoid self condensation during its attachment at the surface of the
support, the terminal amino group is usually protected using a Fmoc group.
The resulting protected photolinker, called PL1-Fmoc (Figure 2.3), is commer-
cially available as 4-(4-(1-(9 fluorenylmethyloxy carbonylamino)ethyl)-2-meth-
oxy-5-nitrophenoxy) butanoic acid (CAS: 162827-98-27). Its synthesis [28,29] is
not presented here as this photolinker will be used only to prove the surface
attachment by the removing of the Fmoc group which gives a easily quantifiable
fluorescent adduct.
O
O
HO
O
N
H
O
O
NO2
Figure 2.3: Photolinker PL1-Fmoc
The second photolinker model, called PL2, is the 4-(4-(1-hydroxyethyl)-
2-methoxy-5-nitrophenoxy) butanoic acid (CAS: 175281-76-2). It consists on
the hydroxy equivalent of PL1 (Figure 2.4). PL2 is also commercially available
and makes the release of carboxylic acids, alcohols and amines possible. PL2 is
known to have a short photocleavage time of 1 to 3 h [19] and also to be cleaved
by photolysis in aqueous solvents.
O
O
HO
O
OH
NO2
Figure 2.4: Photolinker PL2
Its synthesis is herein fully described [19,20,22,27,30,31]. A 4 steps synthesis was
performed (Figure 2.5) consisting in a Williamson ether reaction between apoc-
ynin and ethyl-4-bromobutyrate followed by a nitration of the benzyl ring. The
apocynin ketone moiety is then reduced and the ester bond is finally hydrolyzed.
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O
O
Br
+
OH
O
O
a
O
O
O
O
O
(1)
b
O
O
O
O
O
NO2
(2)
c
dO
O
HO
O
OH
NO2
(4)
Figure 2.5: General scheme of the photolinker synthesis
Reagents are herein listed: (a) K2CO3, DMF ;
(b) 70% HNO3/Ac2O (20:7/v:v), 0 ℃ ;
(c) NaBH4, THF/MeOH (2:1/v:v) ; (d) NaOH
2.3 Results and discussion
2.3.1 Characterization
The model photolinker PL2 was produced in gram scale with an overall yield
for the four steps of 77.39%. Considering this success, a scale-up production
can be envisaged and a significant improvement of the yield is expected using a
better control of the reaction and recrystallization parameters.
2.3.2 Synthesis
2.3.2.1 Ethyl-4-(4-acetyl-2-methoxyphenoxy) butanoate
The first step of the synthesis, which consists in the coupling of apocynin and
ethyl-4-bromobutyrate [18,19,27], is quantitative.
The Williamson ether synthesis, a SN2 reaction, involves the reaction be-
tween an alkoxide ion and a primary alkyl halide. In this reaction, the alkoxide
ion is produced in-situ.
26
ALTHERAS Chapter 2
2.3.2.2 Ethyl-4-(4-acetyl-2-methoxy-5-nitrophenoxy) butanoate
The second reaction is a nitration of the benzyl ring. In a first time nitric
acid and acetic anhydride react together to give first dinitrogen pentoxide and
acetic acid. In the absence of added acetic acid, this pentoxide reacts with
acetic anhydride to give, in an exothermic reaction, almost quantitatively acetyl-
nitrate [32].
It is well known that as solvent, acetic anhydride is particularly efficient in
ring ortho-position nitration using relatively mild conditions. The mixture of
nitric acid and acetic anhydride [19,32] was preferred to other methods using only
nitric acid [22,31] or nitric acid in dichloromethane [27].
2.3.2.3 Ethyl-4-(4-(1-hydroxyethyl)-2-methoxy-5-nitrophenoxy) bu-
tanoate
The third step is the reduction of the keto group by NaBH4. According to Paul-
ing scale, boron has an electronegativity around 2.04 which is lower than that
of hydrogen (2.20). As a consequence, the B-H bond is polarized with the boron
positive and the hydrogen negative. For this reason, the electronic situation in
this reaction can be compared to the electronic situation in a Grignard reagent
and the B-H bond acts as a source of hydride ion.
2.3.2.4 4-(4-(1-Hydroxyethyl)-2-methoxy-5-nitrophenoxy) butanoic
acid
The final step consists in the deprotection of the carboxylic acid moiety. This
reaction is known as ester hydrolysis, or saponification. The carbonyl gives the
corresponding sodium carboxylate which is then protonated by the HCl, giving
PL2.
2.4 Experimental section
2.4.1 General materials and methods
2.4.1.1 Chemicals
Ethyl-4-bromobutyrate: 98% (Alfa Aesar GmbH & Co KG, Karlsruhe, D) ;
DMSO-d6 : cont. 0.03%(v:v) TMS, 99.8 atom% D (ARMAR AG, Döttingen,
CH) ; HCl: ROTIPURAN® ≥ 32%, p.a., ISO ; NaCl: ≥ 99%, Ph.Eur., USP
(Carl Roth GmbH & Co. KG, Karlsruhe, DE) ; DMF: Baker Analysed® A.C.S.
Reagent; Hexane: (95% n-hexane), HPLC ; HNO3: 69.0-70.0%, Baker Instra-
Analysed® Reagent ; MeOH: Baker Analysed® LC-MS Reagent ; THF: Baker
Analysed®A.C.S. Reagent (Mallinckrodt Baker B.V., Deventer, NL) ; NaOH: so-
lution 1 mol·l−1 (1N), BASIC (Scharlab SL, Barcelona, ES) ; Apocynin: ≥ 98% ;
Ac2O: puriss. p.a., ACS reagent, ≥ 99.0% (NT) ;
EtOAc: puriss. p.a., ACS reagent, ≥ 99.5% (GC) ; K2CO3: purum p.a., anhy-
drous, ≥ 99.0% (T) ; NaBH4: purum p.a., ≥ 96% (gas-volumetric) ; Na2SO4: ACS
reagent, ≥ 99.0%, anhydrous, granular ; PL2 (4): ≥ 98.0% (HPLC) (Sigma-
Aldrich Chemie GmbH, Buchs, CH) were used as received. Milli-Q water with
resistivity of more than 18.2 MΩ·cm was provided by a Millipore Milli-Q filtering
system with filtration through a 0.22 µm Millipak filter.
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2.4.1.2 Characterization
Synthesized products were characterized by 1H and 13C NMR spectra. (Ap-
pendix A for raw material NMR analysis). For the final product, a comparison
was realized with the commercially available PL2. NMR spectra were measured
with a Brucker AV-200 (200 MHz), and chemical shifts are reported in ppm
downfield from internal TMS reference. Abbreviations used are s = singlet,
d = doublet, dd = doublet of doublets, t = triplet, dt = doublet of triplet,
q = quadruplet, m = multiplet.
2.4.2 Synthesis
2.4.2.1 Ethyl-4-(4-acetyl-2-methoxyphenoxy) butanoate
To a stirred solution of apocynin and K2CO3 in DMF, ethyl-4-bromobutyrate
was added dropwise in a moderated exothermic reaction. After 20 hours of reac-
tion at room temperature, water (400 ml) was poured in the solution until total
dissolution of the observed solid. The obtained solution was then extracted with
EtOAc (3 x 200 ml) and the organic phase evaporated.
The resulting yellow solution was partitioned between EtOAc (50 ml) and
saturated NaCl solution (6 x 100 ml) to remove traces of DMF [19]. The organic
phase was finally dried over Na2SO4 and evaporated until obtaining the keto-
ester (1) (Figure 2.6) as yellowish oil which solidifies at room temperature (crude
yield = 100%).
Amount Mw (g·mol−1) CAS
Apocynin 30.0875 g 166.1739 498-02-2
DMF 140 ml 73.0937 68-12-2
Ethyl-4-
bromobutyrate 38.7340 g 195.0543 2969-81-5
EtOAc — 88.1051 141-78-6
K2CO3 38.4183 g 137.9121 584-08-7
NaCl — 58.4427 7647-14-5
Na2SO4 — 142.0421 7757-82-6
(1) 51.0000 g 280.3163 174884-21-0
7
O
6
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3
O
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O
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15
9
8
Figure 2.6: Ethyl-4-(4-acetyl-2-methoxyphenoxy) butanoate (1)
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1H-NMR (200 MHz, DMSO-d6 δ) 1.19 (t, J = 7.1 Hz, 3H, H1), 2.00 (dt,
J = 7.3 Hz, J = 6.6 Hz, 2H, H5), 2.47 (t, J = 7.3 Hz, 2H, H4), 2.53 (s, 3H,
H15), 3.82 (s, 3H, H13), 4.07 (q, J = 7.1 Hz, 2H, H2), 4.08 (t, J = 6.6 Hz, 2H,
H6), 7.05 (d, J = 8.4 Hz, 1H, H8), 7.45 (d, J = 2.1 Hz, 1H, H11), 7.60 (dd,
J = 8.4 Hz, J = 2.1 Hz, 1H, H9).
13C-NMR (200 MHz, DMSO-d6 δ) 14.04 (C1), 24.10 (C5), 26.25 (C15),
30.03 (C4), 55.53 (C13), 59.86 (C2), 67.34 (C6), 110.49 (C11), 111.77 (C8),
122.98 (C9), 129.93 (C10), 148.67 (C12), 152.21 (C7), 172.38 (C3), 196.25 (C14).
2.4.2.2 Ethyl-4-(4-acetyl-2-methoxy-5-nitrophenoxy) butanoate
The previously obtained ethyl-4-(4-acetyl-2-methoxyphenoxy) butanoate (1)
was dissolved in 15 ml of Ac2O and added dropwise to a stirred solution of
70% HNO3 (100 ml) and Ac2O (20 ml) at 0 ℃. After 2.5 hours of reaction, the
solution was poured into 300 ml of cold water, while a yellow precipitate was
observed, and kept at 4 ℃ overnight.
The solid was filtered, washed with water and recrystallized in a MeOH/wa-
ter mixture. Yellow needles of ethyl-4-(4-acetyl-2-methoxy-5-nitrophenoxy) bu-
tanoate (2) (Figure 2.7) were obtained and washed with water (yield = 79.96%) [19].
Amount Mw (g·mol−1) CAS
(1) 5.0000 g 280.3163 174884-21-0
Ac2O 35 ml 102.0886 108-24-7
70% HNO3 100 ml 63.0128 7697-37-2
MeOH — 32.0418 67-56-1
(2) 4.6400 g 325.3138 1031702-80-3
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Figure 2.7: Ethyl-4-(4-acetyl-2-methoxy-5-nitrophenoxy) butanoate (2)
1H-NMR (200 MHz, DMSO-d6 δ) 1.19 (t, J = 7.1 Hz, 3H, H1), 2.00 (dt,
J = 7.3 Hz, J = 6.6 Hz, 2H, H5), 2.47 (t, J = 7.3 Hz, 2H, H4), 2.52 (s, 3H, H15),
3.93 (s, 3H, H13), 4.07 (q, J = 7.1 Hz, 2H, H2), 4.14 (t, J = 6.6 Hz, 2H, H6),
7.22 (s, 1H, H11), 7.63 (s, 1H, H8).
13C-NMR (200 MHz, DMSO-d6 δ) 14.03 (C1), 23.90 (C5), 23.93 (C15),
29.98 (C4), 56.63 (C13), 59.90 (C2), 68.13 (C6), 108.05 (C11), 109.83 (C8),
131.17 (C10), 138.33 (C9), 148.45 (C12), 153.30 (C7), 172.35 (C3), 199.21 (C14).
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2.4.2.3 Ethyl-4-(4-(1-hydroxyethyl)-2-methoxy-5-nitrophenoxy) bu-
tanoate
To a stirred solution of ethyl-4-(4-acetyl-2-methoxy-5-nitrophenoxy) butano-
ate (2) in THF (160 ml) and MeOH (80 ml) was added NaBH4 (1.4256 g)
at room temperature. After one hour of reaction, a second portion of NaBH4
(0.4752 g) was added and the reaction mixture was stirred overnight giving (3)
(Figure 2.8) [19].
Amount Mw (g·mol−1) CAS
(2) 10.0000 g 325.3138 1031702-80-3
NaBH4 1.9008 g 37.8325 16940-66-2
THF 160 ml 72.1057 109-99-9
MeOH 80 ml 32.0418 67-56-1
(3) Not isolated 327.3297 1073426-06-8
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Figure 2.8: Ethyl-4-(4-(1-hydroxyethyl)-2-methoxy-5-nitrophenoxy)
butanoate (3)
2.4.2.4 4-(4-(1-Hydroxyethyl)-2-methoxy-5-nitrophenoxy) butanoic
acid
The previous reaction was followed by the addition of 1N NaOH (85 ml) and wa-
ter (40 ml) to proceed to the saponification of the ester (3) during 8 hours. The
mixture was concentrated under vacuum, acidified with 6N HCl (∼ 17 ml) and
extracted with EtOAc. The combined organic phases were dried over Na2SO4
and evaporated to give a yellow residue. Recrystallization from EtOAc/Hexane
(300 ml/800 ml, respectively) afforded the photolinker PL2 (4) (Figure 2.9)
(yield = 96.31%) [19].
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Figure 2.9: 4-(4-(1-hydroxyethyl)-2-methoxy-5-nitrophenoxy) butanoic
acid (4)
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Amount Mw (g·mol−1) CAS
(3) Not isolated 327.3297 1073426-06-8
EtOAc — 88.1051 141-78-6
Hexane — 86.1753 110-54-3
6N HCl — 36.4609 7647-01-0
1N NaOH 85 ml 39.9971 1310-73-2
Na2SO4 — 142.0421 7757-82-6
(4) 8.8606 g 299.2765 175281-76-2
1H-NMR (200 MHz, DMSO-d6 δ) 1.37 (d, J = 6.3 Hz, 3H, H13), 1.96 (dt,
J = 7.3 Hz, J = 6.6 Hz, 2H, H3), 2.40 (t, J = 7.3 Hz, 2H, H2), 3.91 (s, 3H, H11),
4.07 (t, J = 6.6 Hz, 2H, H4), 5.27 (q, J = 6.3 Hz, 1H, H12), 7.37 (s, 1H, H9),
7.54 (s, 1H, H6), 12.17 (COOH).
13C-NMR (200 MHz, DMSO-d6 δ) 24.04 (C3), 25.11 (C13), 29.94 (C2),
56.05 (C11), 63.89 (C12), 67.95 (C4), 108.52 (C6), 109.17 (C9), 137.99 (C8),
138.92 (C7), 146.21 (C5), 153.45 (C10), 173.95 (C1).
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Chapter 3
Chitosan microporous
structure production
Abstract: This study describes the development of a porous material for drug
immobilization through a photolabile moiety. The material presents high poros-
ity in order to achieve elevated drug loading in a reduced volume and diffusion
pathway for the release. Herein, polymeric porous matrices were obtained using
thermally induced phase separation of a polymer solution and subsequent sub-
limation of the solvent. The chitosan is a natural and biocompatible polymer
presenting interesting properties. Chitosan porous matrices obtained can be
considered as a material with immense possibilities. To improve the results, as
reproducibility and matrices homogeneity, a special cryo-unit, the POMAP, has
been designed. To complete this process, a mathematical model is suggested to
predict heat exchanges occurring during the freezing and influencing the scaffold
properties.
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3.1 General remarks
Polymer materials are well described in TTS as their tunable properties allow
to easily influence the release. In particular, porous scaffolds made of natural
polymers gained attention considering their immense potential for innovative
applications. In the case of drug release engineering, ideal scaffolds present the
following characteristics:
• Three dimensional and highly interconnected porous structure ;
• Excellent biocompatibility ;
• Good mechanical properties ;
• Easy production process to form a variety of shapes and sizes ;
• Suitable surface chemistries for surface modification.
Chitosan, a natural linear polysaccharide similar in structure to cellulose [1],
is composed of randomly distributed β-(1-4)-linked D-glucosamine, or glucosa-
mine (GlcNH), and N -acetyl-D-glucosamine, or N -acetylglucosamine (GlcNAc)
(Figure 3.1). It is obtained by deacetylation of chitin which is a structural com-
ponent of crab and shrimp shells, insects exoskeletons or fungi cell walls [2,3,4,5].
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Figure 3.1: Chitosan obtained by chitin through a deacetylation reaction
Usually considered as the second most abundant polysaccharide in nature [6]
with a annual production, only for the marine resources, estimated to 2.3 mil-
lion tons per year [7] and around 10 billion tons considering the full worldwide
production [2,8], chitin and its derivates are used in a wide variety of fields such
as food science [3,9], water treatment [2,10] or paper industry [2].
Due to remarkable properties such as low toxicity, biocompatibility [11], hemo-
statics [12] and antibacterial effect [13], chitosan is an attractive material for
biomedical applications [14].
The production of chitosan porous structures has several applications such
as support material for surgical reconstruction [6,15], drug therapy systems, syn-
thetic prosthesis, medical devices [4,5,16] or cell culture scaffolds [17,18].
Moreover, it is approved by the FDA for drug delivery and various steriliza-
tion methods such as ionizing radiation, X-ray, heat or chemical methods are
adapted for sterilization of chitosan scaffolds in clinical applications [1].
Finally, chitosan reactivity allows typical reactions of amines thus a lot of
chemical modifications are easily obtained under mild conditions [5,19]. It is also
more reactive than chitin regarding the free primary amino groups regularly
distributed in its molecular chain [4,20,21]. For this reason, chitosan is easily
soluble in aqueous solutions of inorganic and organic acids [20].
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3.2 Strategy
Different techniques exist to create chitosan porous structures such as fiber ex-
trusion, 3D printing [22], electrospinning [23], gas foaming [24] of phase separation.
In particular, the phase separation can be obtained from a chitosan solution us-
ing a pH change to precipitate the chitosan [25] or via thermally induced phase
separation (TIPS) [6,15,16].
The TIPS method is based on a thermodynamic demixing of an aqueous
polymer solution into a polymer rich phase and a polymer poor phase by cool-
ing the solution below its freezing temperature [16]. During the process, polymer
aggregates are formed between growing ice crystals giving a continuous inter-
penetrating network of ice and precipitates. After sublimation of ice, a highly
porous polymer structure is obtained [15]. Due to the ease of chitosan dissolution
in acidic aqueous solutions, TIPS is an interesting way to produceChipM [26].
Many different parameters influence the final morphology of a matrix ob-
tained by TIPS. As an example, the pore structure of the scaffold can be ma-
nipulated by acting on solvent volume fraction, size of the ice crystals, polymer
concentration, etc. However, the fine control of the porous structure remains
difficult.
3.3 Results and discussion
3.3.1 Chitosan characterization
Chitosan physico-chemical properties such as solubility, reactivity or biodegrad-
ability highly depend on its degree of deacetylation (DDA) and degree of poly-
merization (DP).
3.3.1.1 Determination of chitosan DDA
Analytical techniques such as UV or IR spectroscopy [27], chromatography, titra-
tion [10] or NMR [10,11,28] are used to determine chitosan DDA. Among these
methods 1H-NMR is recognized as a particularly potent tool. Reasons include
no need of calibration, no need to know precisely the amount and no purifi-
cation step [11]. 1H-NMR using DCl solution at 70 ℃ is widely accepted for
chitosan NMR [11]. However, this method suffers from long experiment duration
due to significant relaxation time at this temperature. Moreover, although the
high temperature of analysis reduces sample viscosity, the sensitivity decreases
dramatically.
In this study, the acquisition time is reduced by performing the experiment
at 27 ℃ in DCl [11]. Data are treated by measuring proton signal area after
Fourier transformation of the free induction decay (FID) signal. Finally DDA is
calculated (Equation 3.1) using the signal from protons 2 to 6 of both monomers
and the peak of acetyl groups (Figure 3.14) [10].
DDA = 100
[
1− HAC/3
H2−6/6
]
(3.1)
For the chitosan used in this study, the obtained DDA is 81.80%, meaning a
large preponderance of GlcNH units which is in accordance with data provided
by the supplier.
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3.3.1.2 Determination of chitosan DP
According to the supplier, the material used for this study has a molecular
weight comprised between 190,000 and 310,000 g·mol−1. By knowing these
minimal and maximal values, corresponding DP values were calculated using
the relation (Equation 3.2) between monomer molecular weights, DDA and the
amount of water loss as product of the virtual condensation reaction of poly-
merization.
Chitosan DP comes from the relation:
DP = Mwchitosan −MwH2O
DDA MwGlcNH + (1−DDA) MwGlcNAc −MwH2O
(3.2)
Using the values:
Mwchitosan 190,000 - 310,000 g·mol−1
MwGlcNAc 221.20780 g·mol−1
MwGlcNH 179.17112 g·mol−1
MwH2O 18.01528 g·mol−1
The estimated average of the chitosan sample is comprised between 1126 and
1836. It reveals short length polymer chains that will potentially impact on the
properties of the ChipM. This value is also of interest for the determination
of the free amine concentration in chitosan solutions. Indeed, it is generally
accepted that the acid concentration needed to dissolve chitosan is at least
equal to the amine concentration [8].
3.3.2 ChipM production by TIPS method
3.3.2.1 Fixed parameters
Chitosan dissolution is function of parameters that also influence the biocom-
patibility and the microstructure of the material obtained by the TIPS process.
However, this study is mainly focused on the influence of freezing conditions on
the TIPS method rather than on other parameters variations. For this reason,
the following parameters were kept constant.
3.3.2.1.a The acid
Type of the acid
Appropriated solvent systems for chitosan dissolution include hydrochloric acid [26],
oxalic acid [29], acetic acid [18,25,30] and lactic acid [31,32] aqueous solutions. Nev-
ertheless comparisons between scaffolds obtained using lactic and acetic acid
to dissolve the polymer showed that acetic acid based scaffolds are more skin
irritant than lactic acid equivalents [31]. On the same time, scaffolds obtained
from lactic acid solution (LA) are known to be softer, more flexible, pliable and
bioadhesive than the acetic acid equivalent [31]. As a consequence, only LA is
used in this study for the production ofChipM.
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Acid concentration
For polyelectrolytes such as chitosan, the pH of dissolution is not constant [8]
and is highly influenced by the electrolytic dissociation behavior of the polymer.
The relation is well described by Katchalsky’s equation (Equation 3.3) [33,34]:
pH = pK0 − log
(
1− α
α
)
+ 0.4343 ε Ψ0
KB
(3.3)
With pK0 the intrinsic dissociation constant of the monomeric unit, α the
degree of ionization of the polymer, Ψ0 the electrostatic surface potential of the
polyion, KB the Boltzmann constant and ε the electron charge. In the case
of α = 1, the polymer becomes uncharged so ε = 0 and pH = pK0. For chi-
tosan, pK0 ≈ 6.5 [35] and is independent of the DDA [8]. Considering parameters
introduced by Katchalsky’s equation, all solutions were prepared using a LA
concentration of 2%(v:v).
3.3.2.1.b Chitosan concentration
Besides its influence on the pH of the solution, the polymer concentration also
plays a critical role on scaffold properties as the volume fraction of the polymer
may change porosity, pore sizes and surface area of the material. Therefore, the
pore structure can be manipulated by varying the polymer concentration [16].
In this study, the chitosan concentration is kept at 20 g of chitosan per liter of
2%(v:v) LA.
3.3.2.1.c Freeze drying conditions
Once the TIPS occurred, the frozen material is freeze dried to sublimate the ice.
Since the freeze drying process has never been reported as having any influence
on the final structure of the scaffold, the conditions were kept constant for all the
experiments using a normal low pressure sublimation during at least 12 hours.
3.3.2.1.d Washing conditions
After the freeze drying, freshly obtained ChipM appear opaque and inelastic.
In order to be used as drug delivery system, they are hydrated. However,
when immersed in a neutral aqueous medium, they rapidly dissolve, revealing a
structure composed of soluble chitosan lactate [36]. For this reason, dryChipM
are rehydrated in particular conditions.
Several solutions can be used for that purpose among sodium hydroxide
solution [26,32], series of EtOH solutions with a regular increase of water content
(0%, 30%, 50% and 100%) [26,36] or ammonia solution (AS) [12,37]. In this study,
the rehydrating solutions consist on EtOH solutions with a regular increase of
ammonia concentration.
3.3.2.2 Influence on freezing conditions on TIPS process
During the freezing of a chitosan solution, a phase separation occurs and leads to
the demixing of the solution into a non frozen liquid microphase of concentrated
chitosan solution and growing ice crystals.
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The porous structure of theChipM is determined at that stage as the space
occupied by the ice later becomes pores. However the freezing conditions showed
a significant effect on the size of the pores [19,26,38] which consequently influence
tensile properties of the scaffolds [26] and drug release kinetic.
Moreover, pore size, pore shape and porosity are also important as they
define the surface area and, in that case, the amount of amine moieties avail-
able for drug loading. Ice crystals are smaller when they have a short time to
grow [39] resulting in small pores [26]. It has been demonstrated that the final
freezing temperature has a negligible effect compared to the freezing rate which
seems to be the key factor to control the scaffold structure [38,40]. Indeed, the
lower the freezing temperature is, the quicker is the freezing rate. In term of
thermodynamic, the freezing rate reflects the heat transfer rate.
In most of the cases, freezing is an exothermic process. By changing from
liquid to solid state, a solution release heat which is known as latent heat or
enthalpy of solidification. During the TIPS, this released energy creates a local
temperature increase and directly impacts the ice nucleation, ice crystals grow-
ing and finally the structure of theChipM [39,40,41]. For this reason, heat has to
be removed from the freezing liquid otherwise the freezing process stops. Using
the same polymer solution, consisting in 2 g of chitosan dissolved in 100 ml
of a 2%(v:v) LA, three TIPS experiments were conducted with variations in
freezing conditions. In experiments A and B, the chitosan solutions were frozen
respectively by simple cooling at constant temperature T = -12 ℃ in a freezer
and using an uncontrolled cooling rate (Rc) from T0 = -5 ℃ to T1 = -15 ℃.
Experiment C was conducted on a dedicated freezing apparatus, the POMAP.
Using Peltier effect, the POMAP makes it possible to precisely control the
Rc of a solution from T0 = -5 ℃ to T1 = -15 ℃. In experiment C, the cooling
rate is Rc = 1.0 ℃·min−1. For all the samples, a porous top surface, consisting
in open and interconnected pores was observed with important variations in
pore size and shape. On the contrary, for all the samples the bottom surface
shows a skin layer, which can be explained by interaction between mold and
polymer chains.
3.3.2.2.a Experiment A and B
Top surface
Analyzing the optical pictures, ChipM obtained by experiment A (Figure
3.2A0) are much more heterogeneous than matrices produced by experiment
B (Figure 3.2B0). This result confirms that the ChipM structure is highly
dependent of the freezing conditions.
The partial destroying of ChipM in experiment A (Figure 3.2A0) can be
explained by a low and ineffective heat extraction, leading to an increased size of
ice crystals. Since the larger ice crystals push chitosan chains to a greater extent,
they may have destroyed the structure. On the contrary for experiment B
(Figure 3.2B0), the EtOH bath used to cool down the chitosan solution induced
a better heat dissipation and consequently the formation of many nuclei of ice,
resulting in the formation of smaller pores [19].
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A0 B0
Figure 3.2: Optical picture ofChipM (scale bar 10 mm)
A0: Experiment A ; B0: Experiment B
For experiment A, the analysis of the SEM pictures (Figure 3.3AT ) corrob-
orates the presence of large and irregular pores. An explanation would be the
existence of poor contact regions between the mold and the freezer surface re-
sulting in a temperature distribution. This induced a space and time variable
heat transfer through the suspension, leading to heterogeneous nucleation, ice
crystals growing and ultimately pore size distribution.
On the poor contact regions, the heat exchange is ineffective and gives time
to the crystals to grow and reach large size. In experiment B (Figure 3.3BT ), the
previous hypothesis of homogeneous heat removing using EtOH as heat transfer
fluid is confirmed by the presence of regular and small pores. In other words,
the difference in pore size between experiment A and B reflects the different
rates of heat transfer. It follows that a sufficiently rapid rate of cooling better
extracts the latent heat of solidification, preventing the formation of long ice
crystals.
AT BT
Figure 3.3: SEM pictures ofChipM (scale bar 200 µm)
AT : Experiment A, top surface ; BT : Experiment B, top surface
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Bottom surface
As it appears in SEM pictures of the bottom surface (Figure 3.4), both exper-
iments A and B present a similar skin like layer on the side in contact with
the mold during the TIPS process. The reason of the formation of this skin is
not clear but may result from a local increase of chitosan concentration due to
electrostatic affinity between the mold and polymer molecules.
AB BB
Figure 3.4: SEM pictures ofChipM (scale bar 200 µm)
AB : Experiment A, bottom surface ; BB : Experiment B, bottom surface
Differences between experiment A and B bottom surfaces can derive from the
cooling rate as in both cases the bottom of the mold is the first part subjected
to the cooling. In experiment A (Figure 3.4AB), the freezing time, few hours,
leaves the time to polymer chains to diffuse and cover completely the mold. In
the case of experiment B (Figure 3.4BB), a faster freezing implies a short time
for polymer chains rearrangement. For this project the presence of that skin
is not a problem as the drug delivery can be made from the top side of the
ChipM. However, it can be avoided by using specials procedures [38].
Cross section
In order to fully describe the influence of the freezing conditions on the struc-
ture of theChipM, cross section SEM pictures of experiments A and BChipM
were taken. In experiment A (Figure 3.5AS), a multi layer structure is visible.
However, ChipM obtained in experiment B (Figure 3.5BS) shows a highly in-
terconnected and fine porous structure.
This difference is directly attributable to the freezing conditions and in par-
ticular to a more efficient heat removing in experiment B. This comparison con-
firms the hypothesis of heat exchange influence in the final ChipM structure.
Indeed, it is clearly perceptible that a non efficient heat transfer in experiment
A gave time to ice crystals to reach a millimeter size while crystals obtained in
experiment B only grew until dozens of micrometers.
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AS BS
Figure 3.5: SEM pictures ofChipM (scale bar 200 µm)
AS : Experiment A, section ; BS : Experiment B, section
Experiments A and B demonstrate that the difference in structures produced
by the TIPS method is mainly influenced by the way of evacuating the heat
released. In experiment B, EtOH is a better heat transfer fluid than air used
for experiment A. As a consequence, homogeneousChipM can be produced by
controlling heat exchange parameters.
3.3.2.2.b Experiment C: ChipM on POMAP
Previous experiments show limitation of using air or EtOH as heat transfer flu-
ids. For this reason, a dedicated apparatus, the POMAP, using thermoelectric
effect of peltier modules (PM) as cooling system, has been designed. In partic-
ular, this device makes it possible to control the mold temperature and remove
easily the heat released during solution freezing. The equipment consists in
an insulated chamber in which the temperature is automatically controlled and
continuously adjusted by the feedback of a thermocouple.
The temperature of the chamber can be monitored from T0 = -5 ℃ to
T1 = -15 ℃ with a precise cooling rate that can go from Rc = 0.1 ℃·min−1 to
Rc = 1.0℃·min−1. In experiment C, the mold, containing the chitosan solution,
was placed into the chamber and after temperature equilibrium, submitted to
a linear temperature decrease at Rc = 1.0 ℃·min−1. TheChipM produced us-
ing the POMAP (Figure 3.6C0) appears significantly much more homogeneous
throughout the entire scaffold thanChipM produced using other techniques.
Looking at the SEM pictures (Figure 3.7), a highly open porous structure
presenting an important interconnectivity can be observed. Images analysis re-
veal a pore aperture around 10 µm which is almost 10 times smaller than the
average pore size obtained in experiment B.
With the POMAP it is possible to achieve high reproducibility as the insulat-
ing chamber limits interactions with external conditions such as temperature or
humidity. Moreover, the possibility to control the cooling rate gives interesting
possibilities to produceChipM having different porous structures.
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C0
Figure 3.6: Optical picture ofChipM (scale bar 10 mm)
Experiment C
By varying only three parameters during the TIPS process among acid (type
and concentration), chitosan (DDA, DP, and concentration) and cooling rate,
many different ChipM can be produced. For this reasons, a nomenclature
describing 550 potentialChipM is proposed (Appendix C).
According to this nomenclature, the matrix
( 2
LA|40
)·ChipM was considered
as a good candidate to pursue this study.
CT1 CT2
Figure 3.7: SEM pictures ofChipM (scale bar CT1 = 200 µm, CT2 = 50 µm)
Experiment C, top surface
3.3.2.3 Washing procedure
Once submitted to the freeze drying, theChipM were thoroughly washed using
a series of EtOH solutions with regular increase of amount of ammonia. During
the last washing step, the pure ammonia solution containing the ChipM is
subjected to vacuum in order to remove trapped air from the matrix.
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This washing procedure is the same for all the samples and does not modify
the porous structure of the obtained matrices as it has been proved by compar-
ison ofChipM SEM pictures before and after it. However, it should be noticed
that the initial ChipM aspect, characterized by an important rigidity and a
low transparency (Figure 3.8a), evolves little by little with the increase of the
ammonia concentration to become highly flexible and transparent in 0.1%(v:v)
AS (Figure 3.8b). Another interesting aspect concerns the role of the vacuum
step as it is clearly obvious that it removes all traces of air (Figure 3.8c).
(a) 100% EtOH (b) 100% AS (c) 100% AS +
vacuum
Figure 3.8: Optical pictures ofChipM, evolution during washing procedure
3.3.2.4 Cutting
The use of a mold to prepare ChipM necessarily induced the presence of a
border effect. This border effect implies a local increase of theChipM thickness
as a consequence of the surface tension of the chitosan solution at the periphery
of the mold.
This thickness discontinuity and the need to work with small pieces of
ChipM for characterization, or for future surface modification, justified the
cutting of the ChipM into small disks. Considering the fine porous structure
of theChipM, two methods were tested to find the less destructive.
The first method consists in a direct cutting after the freeze drying (Dry
state cutting) while in the second method theChipM is cut after the washing
(Wet state cutting). SEM pictures ofChipM cross sections made by these two
methods establish the second method as the best alternative. Indeed, on the
ChipM cut in dry state (Figure 3.9Bs/d) pores appears collapsed and did not
recover their initial shape. On the same time, pores of the ChipM cut in wet
state (Figure 3.9Bs/w) conserved their shape.
Considering these results, the
( 2
LA|40
)·ChipM used in this study were cut
in disks after the washing procedure using a hollow punch. They were then
conserved in hermetically closed glass containers with ammonia solution at 4 ℃
and protected from light.
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Bs/d Bs/w
Figure 3.9: SEM pictures ofChipM from experiment B (scale bar 200 µm)
Bs/d: Section, dry state cut ; Bs/w: Section, wet state cut
3.3.3 Role of latent heat during freezing
As it has been proved by previous experiments, the differences in the pore size
and inner structure of ChipM is influenced by the heat transfer rate during
the TIPS process. A rapid rate of cooling better extracts the latent heat re-
leased during the freezing. For this reason the study of the heat exchange in
the POMAP remains of great importance and a model of heat exchanges should
help to control precisely the structure of theChipM. Furthermore, in order to
scale-up the POMAP cryo-unit a better understanding of the phase change and
a good estimation of the temperature profile during the process is crucial.
In order to describe the role of the cooling rate on the structure ofChipM
produced, a mathematical model based on FEM was developed. The intro-
duction of latent heat in the heat transfer equation over a small temperature
range is a key problem during modeling of a phase change. Moreover, during
the freezing, sudden changes occur in properties of the material such as specific
heat or thermal conductivity.
In this model, the influence of the latent heat on the TIPS process is inves-
tigated and more generally the effect of a phase change on the heat transfer is
studied. Predictions are in accordance with experimental data and a better de-
scription of parameters and geometry should improve the quality of the results.
Herein, the problem was solved using two hypothesis:
• Freezing of pure water instead of acidic polymer solution ;
• Simplified geometry (2 mm of aluminum, 2 mm of water and 1 mm of air).
3.3.3.1 Prediction results
This model uses FEM to solve heat equation in a one dimensional geometry
for which thermodynamic characteristics are function of the position and of the
time. Computation results (Figure 3.10) show interesting heat transfer through
the simplified geometry.
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Following the initial state, where the entire system is at the same tempera-
ture T0 = -5 ℃, the temperature imposed at the bottom of the aluminum plate
(x = 0 mm) regularly decreases with a cooling rate Rc = 1 ℃·min−1. Under
these conditions, the bottom part of the plate reaches the final temperature
T1 = -15 ℃ after τ = 600 s.
Figure 3.10: Temperature profile estimates using FEM model
[0 mm ; 2 mm] → Aluminum, [2 mm ; 4 mm] → Water, [4 mm ; 5 mm] → Air
Between t = 280 s and t = 360 s, a visible temperature change appears in
the aluminum plate (x = 1.5 mm) and the temperature decreases slowly after
that point. This corresponds to the time at which the water begins to freeze
and releases latent heat. In the first seconds of the freezing, the temperature of
the water (x = 3.0 mm) suddenly increases from T = -8.82 ℃ at t = 300 s to
T = -8.55 ℃ at t = 330 s (Figure 3.11), before going down to T = -9.14 ℃ in
less than 10 seconds at t = 340 s. This change is explained by the heat released
during the phase change.
However, the freezing continues as the temperature of the water/ice stays
around T = -10.00 ℃ during 300 seconds. This period is visualized as a steady
state and the heat released by water is absorbed by surrounding ice crystals
which melt and freeze again in a cyclic way until the cooling dissipates all the
energy from the system as it can be observed after 850 seconds when the entire
systems reaches T = -15.00 ℃. This is also confirmed by the cooling delay in
the aluminium plate (x = 1.5 mm).
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Figure 3.11: Detail of temperature profile estimates using FEM model
(from figure 3.10)
3.3.3.2 Comparison with experimental results
By plotting the curves in a different way (Figure 3.12), the effect of the phase
change in the temperature profile is more visible. While subjected to the tem-
perature decrease in x = 0 mm, the system follows the decrease until the tem-
perature of the solution reaches T = -9.00 ℃ (The transition interval was fixed
to dT = 2 K and centered in Ttrans = -10.00 ℃ for this model). At that point,
the solution begins to freeze and the latent heat is released, increasing the tem-
perature of the solution and of the mold. In the model, the linear dissipation
of the energy (x = 0 mm) explains the steady state observed while the phase
separation occurs. A final temperature drop brings the entire system to the
final temperature when the TIPS is finished at t = 850 s.
The model predictions are validated by experimental data (Figure 3.13).
Indeed, the temperature measured by the thermocouple in the POMAP is also
characterized by a temperature increase around t = 350 s and a cooling delay
until t = 850 s. It is important to notice that the experimental data were
measured in the 6 mm aluminum plate of the POMAP. Moreover, the chitosan
solution is not in direct contact with it but placed in a mold that adds 2 mm of
steel between the thermocouple and the solution. This difference shows that the
heat released experimentally is more important than in the model. However,
this difference can be explained by the approximations of the model.
50
ALTHERAS Chapter 3
Figure 3.12: Temperatures estimates using FEM model
(from figure 3.10 cross section)
Figure 3.13: Experimental temperatures in POMAP
Further studies would make it possible to introduce the latent heat of demix-
ing for the chitosan [42] and for the lactic acid.
Finally, the porous structure of the scaffold produced using the TIPS method
can be modified by controlling the area of the latent heat peak. A fine control
of this peak area, for example by increasing the PM capacity during the phase
change, should allow a perfect control of the pore structure of the scaffold.
Significant improvements of the POMAP prototype are in progress to further
optimize the system.
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3.4 Experimental section
3.4.1 General materials and methods
3.4.1.1 Chemicals
DCl: 20%(w:v), in deuterium oxide, 100 atom% D ; D2O: 99.8 atom% D ;
TSP-d4 : 99 atom% D (ARMAR AG, Dottingen, CH) ; Ammonium hydroxide
solution: ACS reagent, 28.0-30.0% NH3 basis ; Chitosan: medium molecu-
lar weight (190,000 - 310,000 g·mol−1) with a DDA between 75% and 85% ;
DL-lactic acid: ∼ 90% (T) (Sigma-Aldrich Chemie GmbH, Buchs, CH) were
used as received. Milli-Q water with resistivity of more than 18.2 MΩ·cm was
provided by a Millipore Milli-Q filtering system with filtration through a 0.22 µm
Millipak filter.
3.4.1.2 Characterization
1H-NMR spectra were recorded at 27 ℃ on a Bruker AVIII-600 (600 MHz).
Acquisition time (AQ) and relaxation delay (D1) were set to 1 s and 12 s respec-
tively. Using 90° pulses, 128 scans were acquired (experiment time = 28 min
so ∼ 13 seconds per pulse). The spectral width and data points were set to
8,000 Hz and 32,000 points respectively. Chemical shifts are expressed in ppm
downfield from internal TSP-d4 (0.00 ppm) reference. SEM micrographs were
obtained using a Supra 40 (Carl Zeiss AG, Germany). Samples were coated
using a gold sputter (45 s, 20 mV) prior to observation at 10 kV.
3.4.2 Chitosan characterization
5 mg of chitosan were dissolved in a NMR tube containing a 2%(v:v) DCl
solution in D2O and heated at 70 ℃ for one hour to speed up the dissolution.
By working at 27 ℃, the solvent residual peak (5.04 ppm) moves away from the
integration area. As the data treatment is realized between 1.7 ppm and 4.4 ppm
this method allows measurement with higher precision even with chitosan having
high water content. The DDA value was determined from the relative integrals
of combined H2-H6 protons (Figure 3.14) and acetyl groups, including N -acetyl
and AcOH. Indeed, the acidic conditions lead to the hydrolysis of some of the
N -acetyl groups and finally to the production of free AcOH. Therefore, both
the N -acetyl and the AcOH signals were considered for the signal integration.
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Figure 3.14: Labelled chitosan structure
1H-NMR (600 MHz, D2O/DCl δ) 2.08 (CH3, NAc), 2.22 (AcOH), 3.20
(H2, GlcNH), 3.77 (H3-H6), 3.93 (H2, GlcNAc), 4.58 (H1, GlcNAc), 4.90 (H1,
GlcNH).
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3.4.3 ChipM preparation
3.4.3.1 Solution preparation
3.4.3.1.a Lactic acid solution (LA)
The 2%(w:v) LA was prepared by diluting 2 g of acid with water for a total
volume of 100 ml. The use of a (w:v) concentration is justified by the viscosity of
the lactic acid which makes the volume measurement difficult. Once prepared,
the pH of the solution was compared to the predicted pH value which is about
2.28 ± 0.050 (Appendix B).
3.4.3.1.b Ammonia solution (AS)
The 0.1%(v:v) ammonium hydroxide solution was prepared by diluting 100 µl
of ammonia with water for a total volume of 100 ml. Once prepared, the
pH of the solution was compared with the predicted pH value which is about
10.70 ± 0.0007 (Appendix B).
3.4.3.1.c Chitosan solution
Dissolution
Chitosan solutions were prepared by dissolving 2 g of the polymer in 100 ml of
LA. The final volume is not of 100 ml so the solution is not called X%(w:v).
Clarification and degassing
After dissolution, chitosan solutions contained impurities and air bubbles. For
the removal of trapped air, sonication appeared as a good alternative [30]. How-
ever, it does not remove solid impurities. Thus chitosan solutions were cleared
and degassed by centrifugation at 3,000 rpm for 15 minutes [26].
3.4.3.2 ChipM production by TIPS
Three experiments were conducted to study the influence of freezing conditions
on the ChipM structure. The volume and composition of the solutions are
identical and the mold used to freeze them is the same. The freezing conditions
are presented below:
Experiment Freezing conditions
1 Constant temperatureT = -12 ℃ in a freezer
2 Uncontrolled cooling ratefrom T0 = -5 ℃ to T1 = -15 ℃
3 POMAP, controlled cooling ratefrom T0 = -5 ℃ to T1 = -15 ℃
After the freezing steps, the frozen chitosan solutions were submitted to
freeze drying during at least 12 hours using the same conditions.
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3.4.3.2.a Molding
The mold used for this study consists of a stainless steel cylindrical flat bottom
container (external ∅ = 112.25 mm, internal ∅ = 91.25 mm, bottom thick-
ness = 2mm). For all experiments, the mold was carefully filled with 13 ml
of chitosan solution, giving ∼ 2 mm thick solution film. Because of the high
viscosity of the chitosan solution, a volumetric pump was necessary to obtain a
precise volume determination. Once the mold was filled, the solution was gently
distributed on the recipient by tilting it.
3.4.3.2.b TIPS process
Experiment A and B
For the experiment A, the mold was kept in the freezer at T = -12 ℃. The
complete freezing of the chitosan solution was observed after three hours. In
experiment B, the mold was initially exposed to an EtOH bath at T0 = -5 ℃
using an external cooling device that controlled the temperature of the EtOH
bath through a jacketed reactor vessels. After the equilibrium of temperatures,
the EtOH bath was cooled down from T0 = -5 ℃ to T1 = -15 ℃. However,
using this method the cooling rate could not be controlled by the cooling device
as its capacity depends of the ambient temperature. Basically a minimum of
40 minutes was necessary to reach the final temperature.
Experiment C
The POMAP cryo-unit (Figure 3.15) consists of a thermally insulated chamber
in which a cooling unit using PM is incorporated. The bottom part of the PM
is maintained at T = -15℃ using an external cooling device. The advantages of
the PM are their great sensitivity to any temperature change and the possibility
to impose a controlled cooling rate, here from T0 = -5 ℃ to T1 = -15 ℃.
A
B
Isothermal
chamber
Stainless steel
mold
Aluminum
plate
Aluminum
heat
exchanger
PM
PM
temperature
control
Cooling
circulator
Figure 3.15: Schematic view of the POMAP for production ofChipM
PM: Peltier modules ; A: feed back from temperature sensor ;
B: continuous adjustment of PM temperature
For the experiment C, the chitosan solution was frozen using the POMAP.
In that case, the mold was placed in the chamber at T0 = -5 ℃ until the
equilibrium. A linear decrease of the temperature was finally applied to the
bottom of the mold with a pre-determined cooling rate Rc = 1 ℃·min−1 until
T1 = -15 ℃ were reached.
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The temperature sensor allows at the same time the temperature determi-
nation in the aluminum plate and helps to adjust continuously the temperature
of the chamber. According to the nomenclature (Appendix C), the resulting
material for experiment C is called
( 2
LA|40
)·ChipM.
The number 2 corresponds to the concentration of acid solution used to
dissolve chitosan, here 2%(w:v), LA is the lactic acid solution. The number 40
describes on the same time the cooling rate and the mass of chitosan dissolved
in 100 ml of LA as the 40th column on the nomenclature table.
3.4.3.2.c Washing
Once the freeze drying was realized, the obtained ChipM were immediately
immersed in dry EtOH to avoid contact with humidity of the air. They were then
submitted to a series of washing baths under gentle shaking during 20 minutes
according to the procedure:
Wahsing step Bath composition Volume
1 100% EtOH
2 100% EtOH 65 ml
3 EtOH/AS (7:3/v:v) (5 x chitosan
4 EtOH/AS (1:1/v:v) solution volume)
5 100% AS + vacuum
The final vacuum step helps to remove air bubbles [36]. The final ChipM
were kept in fresh ammonia solution, at 4 ℃ [37] and were protected from light.
Cutting
ChipM were cut in small disks using a hollow punch or a scalpel.
3.4.3.3 Characterization by electron microscopy
In all cases,ChipM were freeze dried a second time, directly after the washing
step or after cutting, before being imaged by SEM.
3.4.4 Mathematical modelling of the TIPS
In order to describe theChipM formation by TIPS and the release of heat dur-
ing, a mathematical model based on FEM using COMSOL software is proposed.
3.4.4.1 Geometry and parameters definition
3.4.4.1.a Geometry
In order to model the freezing of a water film, a one dimensional geometry was
created. This geometry consists in three layers which represent, in order, an
aluminum plate (LAl = 2 mm), a water film (LH2O = 2 mm) and finally a thin
layer of air (LAir = 1 mm) giving to the system a full size of Ltot = 5 mm.
55
Chapter 3 ALTHERAS
3.4.4.1.b Thermodynamic parameters
The parameters introduced in the model are ρ the density in kg·m−3, Cp the
specific heat capacity in J·kg−1·K−1, T the temperature in K, and k the thermal
conductivity in W·m−1·K−1. The values are given later as constants or functions
of temperature and pressure, for air and aluminum. In the case of the water, the
phase change induces its simultaneous presence in liquid and solid state with
corresponding values:
Water in liquid state (liq) Water in solid state (sol)
ρliq = 997 kg·m−3 ρsol = 918 kg·m−3
Cpliq = 4179 J·kg−1·K−1 Cpsol = 2052 J·kg−1·K−1
kliq = 0.613 W·m−1·K−1 ksol = 2.31 W·m−1·K−1
As a consequence, CpH2O, kH2O and ρH2O are volume average of the form:
CpH2O = θliq Cpliq + θsol Cpsol (3.4)
kH2O = θliq kliq + θsol ksol (3.5)
ρH2O =
θliq ρliq Cpliq + θsol ρsol Cpsol
θliq Cpliq + θsol Cpsol
(3.6)
where θ is the volumetric content of liquid or solid water in function of the
temperature (Figure 3.16). Here the temperature of the transition is set as
observed experimentally so Ttrans = -10 ℃.
Figure 3.16: Volumetric content in liquid and solid water in function of the
temperature
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3.4.4.2 Meshing and mathematical modelling
3.4.4.2.a Boundary conditions
During the liquid to ice phase change, the density is modified, resulting in a
volume expansion. To solve the heat equation, the Lagrangian coordinates are
more appropriated since the deformation do not need to be taken into account.
After an equilibrium time of t0, the initial temperature of the system is
stable and fixed at T0 = -5 ℃. In the POMAP, the temperature in x = 0 mm
decreases with a rate Rc = 1.0 ℃·min−1 until the final temperature T1 = -15 ℃
(Figure 3.17, in blue) is reached. On the other side, the top part of the system
is considered as perfectly insulated. As a consequence, the boundary conditions
for this model are:

n · (−k∇T ) = 0 x = 5 mm
τ =
∣∣∣∣T1 − T0Rc
∣∣∣∣
T0
T0 −Rc t
T1
t < t0
t0 ≤ t ≤ t0 + τ
t > t0 + τ
x = 0 mm
(3.7)
However, the FEM model is not able to work with the discontinuities of this
piecewise function. To avoid this, the temperature decrease was modeled by a
smoothed sigmoidal function Timp(t) (Figure 3.17, in green) that also brings
the temperature from T0 = -5 ℃ to T1 = -15 ℃ in τ = 600 s but without
discontinuity.
Figure 3.17: POMAP temperature piecewise function and model smoothed
function Timp(t)
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As a consequence, the boundary conditions become:

n · (−k∇T ) = 0 x = 5 mm
τ =
∣∣∣∣T1 − T0Rc
∣∣∣∣
T0
Timp(t)
T1
t < t0
t0 ≤ t ≤ t0 + τ
t > t0 + τ
x = 0 mm
(3.8)
3.4.4.2.b Phase change
During a phase change, energy is released. This energy is called latent heat of
fusion and in the case of water λ = 333.5 kJ·kg1. In the model the latent heat
of fusion λ is incorporated in CpH2O which becomes:
CpH2O = θliq Cpliq + θsol Cpsol + λ D(T ) (3.9)
By adding the function D(T) in K−1, this expression of the specific heat
capacity describes the release of the latent heat as a normalized pulse around
the temperature transition dT = 2K where liquid and solid coexist.
However, the integral of the function D(T) must equal unity to satisfy the
following: ∫ T1
T0
ρH2O D(T ) λ dT = ρH2O λ (3.10)
3.4.4.3 Generalized description on COMSOL
A one dimensional geometry of the system was created as shown in the table
3.1. The mesh size was optimized for solution with 150 elements (maximum size
0.335 mm, minimum size 0.0015 mm) using the functions and the parameters
describes previously.
3.4.4.4 Data treatment
A series of curves giving the temperature as function of the distance every 5
seconds during ttot = 1,000 s were collected. This corresponds to t0 = 200 s,
τ = 600 s and another waiting time of t = 400 s to reach the equilibrium.
Data were converted on the IGOR-pro software to obtain a 3D surface giving
the temperature as function of time and distance T = f(x,t).
Using this scatter plot, the isothermal contour plot was extracted as RGB
values to describe the temperature, from T0 = (1,0,0)RGB to T1 = (0,0,1)RGB
(Figure 3.10).
Finally, the curves giving T = f(t) for x = [0.5;1;1.5;2.5;3;3.5;4.5] were iso-
lated (Figure 3.12).
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Boundary
n · (−k∇T ) = 0
—
Lair: 1 mm
ρair Cpair
∂T
∂t
= ∇ · (−kair ∇T ) +Q
Rair = 1.4
Cpair = f(T) by default
ρair = f(P,T) by default
kair = f(T) by default
LH2O: 2 mm
ρH2O CpH2O
∂T
∂t
= ∇ · (−kH2O ∇T ) +Q
RH2O = 1
CpH2O = f(θliq,θsol)
ρH2O = f(θliq,θsol)
kH2O = f(θliq,θsol)
LAl: 2 mm
ρAl CpAl
∂T
∂t
= ∇ · (−kAl ∇T ) +Q
RAl = 1
CpAl = 900 J·kg−1·K−1
ρAl = 2700 kg·m−3
kAl = 160 W·m−1·K−1
Boundary
T(t) = Timp(t)
—
Table 3.1: Mathematical description of the model
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Chapter 4
Photosensitive ibuprofen
loaded porous structure
Abstract: This chapter presents the surface modifications of chitosan porous ma-
trices. The modifications described are of two types. One concerns a primary
coupling of photolinkers PL1 and PL2 or the acetylation of the matrices. At the
same time, the use of PL1-Fmoc and its deprotection makes the quantification
of the surface loading possible. The second type of the surface modification is
the attachment of ibuprofen at the very end of the photolinker PL2. Ibuprofen
loaded matrices will then be used to demonstrate the drug release upon illumi-
nation of the matrices. The suggested chemistry, based on peptide synthesis, is
very flexible and one-pot coupling conditions have been developed using simple
and highly efficient conditions to obtain drug loaded matrices.
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4.1 General remarks
Solid phase surface modification is known since the 60’s [1,2,3]. This method
allows an easy production of the final product with high purity as a simple
washing of the support is sufficient to remove excess reagents.
The first use of solid phase synthesis for peptide synthesis was quickly fol-
lowed by the introduction of photolinkers [4]. Reaction between an amine and
a carboxylic acid is thermodynamically not favorable as an acid-base reaction
normally occurs to form a stable salt. For this reason, amide bond formation
usually requires activation of a carboxylic acid moiety in the presence of cou-
pling reagents. Activation consists of the replacement of the hydroxyl group
of the carboxylic acid with a leaving group. The in-situ activation have been
described using carbodiimides, phosphonium or phosphinic salts such as the Cas-
tro’s reagent (BOP). However, since the BOP is known to produce the highly
toxic HMPA as by-product [5,6], other related salts that produce less toxic wastes
have been developed [7].
This is the case for aminium/uronium salts such as HATU, HBTU or TBTU.
Indeed in the presence of tertiary amine bases such as NMM, DIPEA or TEA [7],
these salts have proved to be more effective than those carried out with phospho-
nium reagents or carbodiimides. One of the most reactive, HATU, is expensive
and an alternative is the HBTU (Figure 4.1a). However, since these salts are
known to be guanidylation agents, it has become popular to introduce auxil-
iary nucleophiles as for the carbodiimides, to avoid side reactions [7]. The most
commonly used additive remaining the HOBt (Figure 4.1b).
N
O
N
N
⊕
N
N
PF	6
(a) HBTU
N
OH
N
N
(b) HOBt
Figure 4.1: Chemical structures of coupling reagents
4.2 Strategy
Surface immobilization represents a key step to obtain the proof of concept for
the ATTS. Since the photolinker synthesis has been established (Chapter 2)
and the polymer support production proposed (Chapter 3), this part consists
to gather them in order to produce photosensitive drug loaded matrices able
to release ibuprofen when exposed to UV light. Considering the wide-spread
use of photolinkers in solid phase peptide synthesis [8,9,10,11] this work is based
on peptide synthesis chemistry. The synthesis method proposed is divided into
primary and secondary coupling reactions.
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The primary coupling, meaning a permanent attachment is realized, with
photolinkers PL1-Fmoc and PL2 onChipM, using the peptide synthesis method
with HBTU, HOBt and DIPEA [5,6]. Another primary coupling, the acetylation
of the chitosan is described to obtain chitin porous matrices.
The secondary coupling reactions are temporal attachment. The only sec-
ondary coupling presented is the immobilization of the drug model, the ibupro-
fen, to the photolabile moiety of the photolinker. This reaction is realized on
PL2 using similar method than for primary coupling. However, in that case the
reaction consists in a Steglich esterification [12].
4.2.1 Solvent system
The choice of the solvent is an important parameter considering the material
and the structure of the support. Indeed, the chitosan is stable in common
organic solvents used for the surface attachment of the photolinker [13,14,15,16],
but its porous structure implies the choice of a solvent in which all compounds
(reagents, reactants and residues) are soluble to avoid any deposition inside of
the structure. DMF is often used in peptide synthesis, but since it is recognized
as possible carcinogen, it tends to be baned from industrial process.
A good alternative, the NMP presents the same characteristics than DMF as
water miscibility and high polarity but with lower toxicity. Finally, the solvent
was the same for all the reactions in order to avoid the time consuming phase
of solvent exchange in the porous structure.
4.2.2 Photolinker coupling on support
The photolinker attachment on the chitosan structure is realized using the well
known solid phase peptide synthesis technique [7,15,16,17,18,19,20]. The coupling
procedure is the same for PL1-Fmoc and PL2. However, in the case of PL1-
Fmoc, the Fmoc group has to be removed after coupling. This deprotection is
usually realized using a base, mainly secondary amines [21].
4.2.3 Drug coupling on photolinker
4.2.3.1 Ibuprofen as drug model
The proof of concept is established by the release of a carboxylic acid bear-
ing molecule from PL2. Ibuprofen, known as 2-(4-(2-methylpropyl)phenyl)
propanoic acid (Figure 4.2), is a non steroidal anti-inflammatory drug used
in the treatment of acute and chronic arthritic conditions and was chosen as
drug model for this study. It is a weak acid (pKa = 4.41), soluble in organic
solvents with variable water solubility at 25 ℃ from 0.19 mg·ml−1 at pH = 1 up
to 1000 mg·ml−1 at pH = 10. Transdermal delivery of ibuprofen using various
formulations has been described in the literature [22,23].
OH
O
Figure 4.2: Chemical structure of ibuprofen
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4.2.3.2 Ibuprofen attachment on photolinker
The attachment of ibuprofen to the photolinker PL2 is achieved using the
Steglich esterification [12]. In this reaction the same reagents as for the amide
bond formation are used but a pyridine derivative, the DMAP is introduced as
a catalyst [24,25].
4.3 Results and discussion
4.3.1 Solvent exchange
After their production by TIPS,ChipM were stored in 0.1%(v:v) AS (Chapter
3). However, before any surface modification, a solvent exchange is necessary
as the chemical reactions are conducted in NMP. Moreover, water traces are
susceptible to disturb coupling reactions. For solvent exchange, ChipM were
soaked in 5%(v:v) DIPEA in NMP [14,15]. As a consequence, the initial trans-
parent and flexibleChipM became hard and non deformable anymore.
4.3.2 Primary coupling on ChipM with PL1
Quantification in solid phase is a problematic topic. PL1-Fmoc is not considered
as a good candidate for the release of drug. However, its reactivity can be con-
sidered as close enough to the PL2 reactivity because of their similar structure.
Its capacity to release the DBF can be used to quantify the surface loading and
to optimize coupling conditions of PL2. The coupling of PL1-Fmoc was realized
onChipM produced using experiment B conditions (Chapter 3).
4.3.2.1 Coupling and deprotection of PL1-Fmoc
The use of chitosan for solid phase peptide synthesis is well reported [14,15,16,26].
For this reason, the coupling reaction of the PL1-Fmoc on ChipM was per-
formed using classical solid phase peptide coupling conditions (Figure 4.3).
NH2 a
b
H
N
O
O
O
NH2
NO2
ChipM · PL1
Figure 4.3: ChipM·PL1 synthesis
Reagents are herein listed:
(a) PL1-Fmoc, HBTU, HOBt, DIPEA in NMP ;
(b) 2%(v:v) DBU in NMP
The coupling agent used was HBTU which is considered as one of the most
efficient coupling agent [20]. At the same time, HOBt was introduced to improve
the yields and DIPEA to activate the PL1-Fmoc. After the reaction, the initial
became yellow which is the characteristic of the sensitive photolinker.
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Qualitatively, aChipM treated under the same conditions but without cou-
pling agent stayed completely white, proving that the photolinker is not trapped
by theChipM walls but coupled to the surface.
The second chemical reaction conducted on the modified ChipM is the
removal of the Fmoc group from the PL1-Fmoc. Usually 20%(v:v) piperidine
in DMF [15,26,27,28] or NMP [29] is used. However, the use of highly concentrated
piperidine solution implies a difficult washing of the porous support. For this
reason, the less volatile and less toxic DBU (Figure 4.4) was preferred [8].
N
N
Figure 4.4: Chemical structure of DBU
Indeed, it was demonstrated that submitting Fmoc protected amino acid to
a 2%(v:v) DBU solution during 5 minutes [28] induced a fast, efficient and quan-
titative Fmoc cleavage [30,31], proving its better efficiency compared to piperidine
cleavage [8,19,32]. Moreover, the resulting DBF product (Figure 4.5) can be pre-
cisely quantified [28,31,32,33,34].
O
O H
N
R
DBU
DBF
Figure 4.5: DBU cleavage of the Fmoc group
4.3.2.2 Quantification of PL1 loading
Several methods are reported for the determination of amine loading on solid
phase using the ninhydrin test [26,35,36] or the bromophenol blue test [37]. An-
other method consists of indirected quantification by the determination of DBF
released after the Fmoc deprotection. However, attempts to DBF isolation re-
sults in an insoluble polymeric species [33].
As a consequence, calibrations were carried out by its in-situ production [28],
submitting Fmoc protected glycine (Gly-Fmoc) solutions to DBU [33] before an-
alyzing DBF concentration by HPLC. As internal standard, a known concen-
tration of anthracene was incorporated. The advantage of the anthracene is
that its peak is close enough to the DBF peak, allowing a complete analysis in
10 minutes.
4.3.2.2.a Calibration
Considering the need of the loading determination with high precision, a cal-
ibration method is suggested. The calculations reveal a Pearson correlation
coefficient ρ2 = 0.999839 proving a good correlation between the DBF concen-
tration in calibration solutions and absorbance signal.
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However, the homoscedasticity test gives χ2OBS = 21.7 > χ25 = 11.1, which
means that at least one non considered parameter intervenes in the calibration.
This can be explained by the method used to prepared the calibration solutions
as the uncertainties on volume increases with the working volume.
Nevertheless, 4 calibration regressions consisting into two linear models and
two quadratic models were established. For the linear model without constant
(1.WOC), the test of validity gives FOBS(1.WOC) = 78.6 > F5,24(0.95) = 2.6.
This value is too high to confirm the rightness of the regression and proves that
the calibration did not reach the quality required.
However, since this 1.WOC model does not modify the proof of concept
results, it is used without correction. Finally, the method proposed reveals
that a correlation coefficient ρ2 close to one is not representative for a good
calibration. The problem met in this study clearly demonstrate the very high
sensibility of this calibration method.
4.3.2.2.b Theoretical loading determination
The theoretical loading is the amount of amino groups per mass unit of chitosan.
This value can be calculated using DDA, DP and Mwchitosan determined in
Chapter 3 and the relation:
nNH2 =
DDA DP
Mwchitosan
(4.1)
Since the chitosan molecular weight Mwchitosan ∈ [190,000;310,000] g·mol−1,
the result is nNH2 ∈ [4.8453;4.8455] mmol·g−1. It is interesting to notice that
the nNH2 value is almost independent of Mwchitosan. This means that if the DP
influences the physical characteristics of theChipM, its impact on the surface
chemistry is low.
By comparing with reported values giving nNH2 ∈ [0.08;0.35] mmol·g−1 [15],
it is clear that all amine moieties are not accessible for chemical reactions. A way
to increase there accessibility is to increase the specific surface of the material.
4.3.2.2.c Quantification
Estimation of ChipM mass
The quantification study was carried on ChipM produced using conditions of
experiment B (Chapter 3). Briefly, a chitosan solution (V = 13.0 cm3) obtained
by dissolving 2 g of polymer in 100 ml of LA was frozen in a stainless steel mold
(internal diameter Ø1 = 9.125 cm), before freeze drying and washing.
In order to simplify calculations a 2%(w:v) chitosan solution without surface
tension is considered. As a consequence, the thickness of theChipM is uniform
and equal to HChipM = 0.199 cm. The matrix was finally cut into disks having
a radius Ø2 = 2.8 cm. The corresponding mass of chitosan in these portions
can be estimated to mchitosan(Ø = 2.8) = 24.481 mg.
Loading results
By working with 5 ChipM in 10 ml of NMP, the quantification of DBF con-
centration gives a loading of 168.99 µmol·g−1.
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This value is comparable with the expected loading found in literature and
stays far from the theoretical loading as it represents ∼ 3.48% of theoretical
amine amount. However, by comparing modification conditions with those used
to obtain a loading close to 350 µmol·g−1 [15], it can be noticed by working with
a 10 times smaller concentration, a good loading value is reached (Table 4.1).
This can be explained by the procedure used to produce the porous matrix as
the specific surface is certainly much higher in this case.
— Experimentalconditions
Conditions from
literature [15]
Base ∼ 30 mM (3 eq.) 400 mM (6 eq.)
Coupling agent ∼ 20 mM (2 eq.) 300 mM (4.5 eq.)
HOBt ∼ 20 mM (2 eq.) 300 mM (4.5 eq.)
Linker ∼ 10 mM (1 eq.) 66.6 mM (1 eq.)
Chitosan 122.40 mg (5ChipM) 150 mg
Loading 168.99 µmol·g−1 80 to 350 µmol·g−1
Table 4.1: Comparisons of experimental conditions with literature
An obvious way to increase the coupling would be to increase the molarity
of the reagents, change the temperature of the reaction [8,15] or use microwave
irradiations [27]. An other option consists to work with a fully deacetylated
chitosan. Moreover, by optimizing the pore size of the support material, an
important increase of the specific surface is expected. This is confirmed by
the pore size observed on ChipM produced on the POMAP (Experiment C,
Chapter 3).
4.3.3 Primary coupling on ChipM with PL2
In this part of the study, the temperature of the reaction was set at 50 ℃,
photolinker concentration was multiplied by 5 and other reactant concentrations
by 7 (Figure 4.6). The coupling of PL2 was realized on ChipM produced on
the POMAP (Experiment C, Chapter 3).
NH2 a
H
N
O
O
O
OH
NO2
ChipM · PL2
Figure 4.6: ChipM·PL2 synthesis
Reagents are herein listed :
(a) PL2, HBTU, HOBt, DIPEA in NMP
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A qualitative observation of the obtained material compared to the mate-
rial produced previously with PL1 shows a really much more efficient load-
ing. Indeed, the
( 2
LA|40
)·ChipM·PL2 is strongly colored in yellow while theChipM·PL1 appears light yellow (Figure 4.7). Difference can come from the re-
ally important excess of reagents, from the temperature at which was conducted
the reaction or from the surface area that should be higher with
( 2
LA|40
)·ChipM.
A B
Figure 4.7: Coupling comparison for PL1 and PL2 onChipM
A:ChipM·PL1 ; B: ( 2LA|40)·ChipM·PL2
4.3.4 Primary coupling on ChipM with acetylation
Among many reactions involved in chitosan modification, the acylation of chi-
tosan has gained special interest [17] since the capping of remaining amine moi-
eties by acetylation gives the possibility to produce water stable chitin porous
matrices. Indeed, free amino groups are responsible for the good solubilization
properties of chitosan in acidic solutions. In the frame of this project, chitin
porous matrices could serve as support for passive TTS by simple loading with
a drug loaded dM.
Many different methods exist for the acetylation of chitosan using mixtures
of Ac2O with DIPEA in DMF [8,9,27,29,38], Ac2O with pyridine [15] or derivates [39]
and also AcOH with coupling agents as for peptide synthesis [40]. Here, a mixture
of Ac2O/DIPEA in NMP [19] was used to convert
( 2
LA|40
)·ChipM into chitin
porous matrices or
( 2
LA|40
)·ChipM·OAc (Figure 4.8).
NH2 a
H
N
O
ChipM · OAc
Figure 4.8: ChipM·OAc synthesis
Reagents are herein listed:
(a) Ac2O, DIPEA in NMP
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4.3.5 Secondary coupling on ChipM PL2 with ibuprofen
Using the
( 2
LA|40
)·ChipM·PL2 previously prepared, ibuprofen loaded matrices
were produced. The chemical reaction involved is an esterification, also known
as Steglich esterification [12]. This reaction is similar to the peptide synthesis
as it consists to activate the carboxylic acid to facilitate the reaction with the
hydroxyl group of the PL2.
Compared to the Fischer esterification, this reaction presents the advantage
to be quantitative, which is particularly interesting for the coupling of expensive
drugs. The reaction (Figure 4.9) was conducted using DIC as coupling agent in
the presence of HOBt [39].
ChipM · PL2 a
H
N
O
O
O
O
ONO2
ChipM·PL2·(Ibu)
Figure 4.9: ChipM·PL2·(Ibu) synthesis
Reagents are herein listed :
(a) Ibuprofen, DIC, HOBt, DMAP in NMP
The quantification of ibuprofen surface loading has not been realized for
reasons evoked before. However, indirect methods based on saponification and
quantification of the released acid in solid phase exist [40]. According to the
nomenclature for secondary couplings (Appendix C), the matrices are called
ChipM·PL2·(Ibu) .
4.4 Experimental section
ChipM used for surface modification were produced using the TIPS method
described in Chapter 3. They were cut in small disks of Ø = 2.8 cm in diameter
using a hollow punch. Differences between ChipM used for surface modifica-
tions come from the freezing procedure.
For PL1 coupling and acetylation reaction,ChipM were obtained using the
experiment B procedure (Chapter 3) while for PL2 and ibuprofen coupling,
ChipM were obtained using the POMAP cryo-unit (Chapter 3).
4.4.1 General materials and methods
4.4.1.1 Chemicals
PL1-Fmoc: (abcr GmbH & Co. KG, Karlsruhe, D) ; TFA: gradient tested for
HPLC peptide and protein analysis, UV cutoff λ = 210 nm (Mallinckrodt Baker
B.V., Deventer, NL) ;
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ACN: CHROMASOLV® gradient grade, for HPLC, ≥ 99.9% ; Ac2O: puriss.
p.a., ACS reagent, ≥ 99.0% (NT) ; Anthracene: analytical standard, for en-
vironmental analysis ; DBU: puriss., ≥ 99.0% (GC) ; DIC: purum, ≥ 98.0%
(GC) ; DIPEA: 99.5% , biotech. Grade ; DMAP: ReagentPlus®, ≥ 99.9% ;
Gly-Fmoc: ≥ 98.0% (T) ; HBTU: ≥ 98.0% (T) ; HOBt: wetted with not
less than 14 wt.% water, 97% ; Ibuprofen: ≥ 98.0% (GC) ; NMP: anhydrous,
99.5% (Sigma-Aldrich Chemie GmbH, Buchs, CH) ; PL2: Obtained by synthesis
(Chapter 2) were used as received. Milli-Q water with resistivity of more than
18.2 MΩ·cm was provided by a Millipore Milli-Q filtering system with filtration
through a 0.22 µm Millipak filter.
4.4.1.2 Characterization
Chromatography were carried using an Agilent 1100 series HPLC instrument
equipped with a high pressure gradient pump, an auto-injector set at 10 µl and
a UV-Visible detector set at λ = 254 nm. The separations were carried out on
a 5 µm Sphereclone ODS (2) column (Phenomex, 150 mm x 4.60 mm i.d.) at
25℃ and eluted at 1.0 ml·min−1 (pressure ∼ 52 bars) using an isocratic mixture
of 30% H2O cont. 0.1%(v:v) and 70% ACN cont. 0.1%(v:v). The column was
coupled to a security guard cartridge system.
The signal measurements were obtained by rationing the areas of the DBF
absorbance signal to the anthracene absorbance signal after baseline correc-
tion on the IGOR-Pro software. The limit integration intervals, determined
by differentiation of the signal curve, were [6.54;7.34] min for the DBF and
[7.34;8.48] min for the anthracene.
Using this method, the blank retention time is t0 = 1.51 min and the re-
tention times are tDBF = 5.42 min and tanth = 6.24 min for the DBF and the
anthracene respectively. The resolution is R = 1.59, which is high enough to be
used.
4.4.2 Solvent exchange
Before surface modifications, theChipM were submitted to a solvent exchange
which consists in soaking theChipM disks in 5%(v:v) DIPEA in NMP during
20 minutes, using 2 ml per ChipM. This procedure was repeated three times
with clean DIPEA/NMP mixture each time.
4.4.3 PL1 coupling on ChipM
4.4.3.1 PL1-Fmoc on ChipM
To a solution of DIPEA and PL1-Fmoc in 8 ml of NMP, were added 5ChipM
(experiment B, Chapter 3). The solution was gently shaken at room temperature
during 15 minutes before adding HBTU and HOBt dissolved in 2 ml of NMP.
After one hour of reaction, the ChipM·PL1-Fmoc were submitted to three
washes with a 5%(v:v) DIPEA/NMP mixture.
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Amount Mw(g·mol−1)
Concentra-
tion CAS
DIPEA 38.7 mg 129.2432 29.94 mM 7087-68-5
HBTU 75.5 mg 379.2518 19.90 mM 94790-37-1
HOBt 27.0 mg 135.1234 19.98 mM 123333-53-9
NMP 10 ml — — 872-50-4
PL1-Fmoc 52.0 mg 520.5305 9.98 mM 162827-98-7
4.4.3.2 Fmoc removing
To a 10 ml solution of 2%(v:v) DBU in NMP, were added 5ChipM·PL1-Fmoc
(experiment B, Chapter 3). The solution was gently shaken at room tempera-
ture. After one hour of reaction, aliquots of the solution were taken out and im-
mediately analyzed by HPLC to quantify the DBF. The obtainedChipM·PL1
were submitted to three washes with a 5%(v:v) DIPEA/NMP mixture.
Amount Mw(g·mol−1)
Concentra-
tion CAS
DBU 0.2 ml 152.2367 133.73 mM 6674-22-2
NMP 9.8 ml — — 872-50-4
4.4.4 Quantification
4.4.4.1 Calibration procedure
4.4.4.1.a Standard solution
Stock solutions
To reduce uncertainties due to the measurement of low mass, concentrated an-
thracene and Gly-Fmoc stock solutions, SA0 and SG0 respectively, were prepared
before being diluted to give SA1 and SG1.
SA0
35.6 mg of anthracene in
10 ml of NMP [Anth]SA0 ≈ 20 mM
SA1
100 µl of SA0 diluted to
10 ml with NMP [Anth]SA1 ≈ 200 µM
SG0
30.0 mg of Gly-Fmoc in
10 ml of NMP [Gly-Fmoc]SG0 ≈ 10 mM
SG1
200 µl of SG0 diluted to
10 ml with NMP [Gly-Fmoc]SG1 ≈ 200 µM
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Calibration solutions
A series of N = 6 calibration solutions SC i were prepared using increasing
volumes VSG1 i of SG1, constant volumes of DBU (VDBU = 200 µl) and SA1
(VSA1 = 1.0 ml) and diluted to 10 ml with NMP.
— VSG1 → SC i [Gly-Fmoc]SCi
SC1 0.00 ml [Gly-Fmoc]SC1 = 0.00000 µM
SC2 0.25 ml [Gly-Fmoc]SC2 = 5.04530 µM
SC3 0.50 ml [Gly-Fmoc]SC3 = 10.0906 µM
SC4 1.00 ml [Gly-Fmoc]SC4 = 20.1812 µM
SC5 1.50 ml [Gly-Fmoc]SC5 = 30.2719 µM
SC6 2.00 ml [Gly-Fmoc]SC6 = 40.3625 µM
Once prepared, calibration solutions were stored at room temperature in the
dark prior to analysis. The analysis were conducted 5 times (p = 5) for each of
the N standard solutions. The obtained signals were called yN,p.
4.4.4.1.b Calculations
The traditional method for regression calculation considers the statistic value
R2, called coefficient of determination, as a good parameter to describe the
validity of a model. However, this value is really difficult to interpret as there
is no limit value. In this study, the quality of the calibration is characterized
using another method which is presented here.
Pearson product-moment correlation coefficient
By defining:
X = 1
N
N∑
i=1
Xi Yi =
1
p
p∑
j=1
yi,j and Y =
1
N
N∑
i=1
Yi (4.2)
with X the average on the N concentrations Xi, Yi the average on p repe-
titions for one concentration Xi, Y the average of the Yi for N concentrations
the variances and covariances are:
Var(X) = 1
N
N∑
i=1
(Xi −X)2 Var(Y ) = 1
N
N∑
i=1
(Yi − Y )2 (4.3)
and Cov(X|Y ) =
N∑
i=1
(Xi −X)(Yi − Y )
N
(4.4)
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The Pearson product-moment correlation coefficient is defined as:
ρ2 =
(
Cov(X|Y )√
Var(X)Var(Y )
)2
(4.5)
Homoscedasticity
When p responses yi,j are determined for the concentration Xi, the standard
deviation can be calculated for this concentration using the relation:
Si =
√√√√ p∑
j=1
(yi,j − Yi)2
νi
with νi = p – 1 the degree of freedom of Si (4.6)
The main idea of the homoscedasticity study is to compare the N standard
deviations. Two different possibilities exist for the study of variance homogene-
ity. The first one is the Bartlett’s test which allows to work with different values
of p. The second one is the Cochran’s test in which all samples must have the
same size p. However, the Bartlett’s test gives the possibility to calculate the
merged standard deviation S∗, determined with the relation:
S∗ =
√√√√ N∑
i=1
νi(Si)2
ν∗
with ν∗ =
N∑
i=1
νi the degree of freedom of S∗ (4.7)
Finally χ2OBS =
1
D
(
ν∗ln(S2∗)−
N∑
i=1
νiln(S2i )
)
(4.8)
with D = 1 +
N∑
i=1
(
1
νi
− 1
ν∗
)
3(N − 1) (4.9)
To determine if the calibration is homoscedastic or not, the χ2OBS is com-
pared to the χ2N−1(0.95) in table of critical values for Pearson correlation. If
χ2OBS > χ
2
N−1, the N standard deviations are not on the same order of mag-
nitude and the calibration has to be repeated. In particular, the reasons of
variation in Yi are different between samples. In that case, this reason must be
identified before continuing.
When χ2OBS < χ2N−1, the N standard deviations are on the same order of
magnitude and the calibration can be made. In that case the Si are considered
as equal to:
S0 =
S∗√
p
and the degree of freedom becomes ν0 = ν∗ (4.10)
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The advantage is that the standard deviation is known more precisely. Here
ρ2 = 0.999839, S0 = 0.0005371924628, ν0 = 24 and χ2OBS = 21.7 > χ25 =11.1.
As a consequence, this calibration can not be considered as homoscedastic.
Regression parameters
The regression model proposed makes it possible to calculate any polynomial
regression. For that study, only 4 different regressions were considered:
Model Type of model Model
1.WIC Linear withconstant effect Y = B1.WIC ·X + A1.WIC
1.WOC Linear withoutconstant effect Y = B1.WOC ·X
2.WIC Quadratic withconstant effect Y = C2.WIC ·X
2 + B2.WIC ·X + A2.WIC
2.WOC Quadratic withoutconstant effect Y = C2.WOC ·X
2 + B2.WOC ·X
The regression parameters are calculated using a matrix least squares method.
The matrix of coefficients Co is given by solving the matrix equation:
Co = (tSS)−1 tS Y (4.11)
With S the matrix of effects and Y the matrix of responses. Detailed calcu-
lations are not presented here. The results are:
For 1.WIC:
Y = 0.02192498762·X + 0.00292215366
For 1.WOC:
Y = 0.02202550669·X
For 2.WIC:
Y = – 0.00002240679177·X2 + 0.02282343312·X – 0.001440693984
For 2.WOC:
Y = – 0.00001959400292·X2 + 0.02267993034·X
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When coefficients are determined, the residual values for each Xi are calcu-
lated:
For 1.WIC:
ei = Yi – Yˆi with Yˆi = B1.WIC ·Xi + A1.WIC
For 1.WOC:
ei = Yi – Yˆi with Yˆi = B1.WOC ·Xi
For 2.WIC:
ei = Yi – Yˆi with Yˆi = C2.WIC ·X2i + B2.WIC ·Xi + A2.WIC
For 2.WOC:
ei = Yi – Yˆi with Yˆi = C2.WOC ·X2i + B2.WOC ·Xi
The residual standard deviation Sr of each model are calculated with:
Sr =
√√√√√√
N∑
i=1
e2i
N − k − 1 with
k1.WIC = 1 k1.WOC = 0
k2.WIC = 2 k2.WOC = 1
(4.12)
Significance of coefficients
The individual significance of each coefficient is then calculated with a Student’s
test. This one is done by calculating the standard deviations of each coefficients
by solving the matrix equation:
Var(Co) = S2r (tSS)−1 (4.13)
Var(Co) represents the matrix of variance/covariance for the coefficients.
Here again the calculations details are not presented. When the variance of
coefficients are known, the standard deviation is deduced by:
SCo =
√
Var(Co) (4.14)
To determine if a coefficient is significant or not, the tOBS(Co) is calculated
for each coefficient using the generalized relation:
tOBS(Co) =
|Co|
SCo
(4.15)
tOBS(Co) is finally compared to the tN−k−1(0.95) in the table of the Stu-
dent’s distribution. If tOBS(Co) > tN−k−1(0.95), the coefficient is considered
as significant. Otherwise, the coefficient can be removed from the model.
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For this calibration the results are:
Model tN−k−1(0.95) tOBS(0.95) Result
1.WIC t4(0.95) = 2.776
tOBS(B1.WIC) = 157.76 significant
tOBS(A1.WIC) = 0.92 not significant
1.WOC t5(0.95) = 2.571 tOBS(B1.WOC) = 256.53 significant
2.WIC t3(0.95) = 3.182
tOBS(C2.WIC) = 3.28 significant
tOBS(B2.WIC) = 80.51 significant
tOBS(A2.WIC) = 0.66 not significant
2.WOC t4(0.95) = 2.776
tOBS(C2.WOC) = 3.93 significant
tOBS(B2.WOC) = 131.80 significant
Models validity
A model must always be validated before being used. This is done by controlling
if the residual values are on the same order of magnitude than uncertainties of
the measurement. The validation of a model can be demonstrated by a Fisher’s
test, in this case the comparison between Sr and S0. To know if a model is valid
or not, the FOBS is calculated with:
FOBS =
(
Sr
S0
)2
(4.16)
The FOBS is then compared to the Fν1,ν2(0.95) in F-tables of Fisher-Snedecor
using ν1 = N-k-1 and ν2 = ν0.
If FOBS < Fν1,ν2(0.95) the model is valid and explains totally the responses
to experimental data. As a consequence, it can be used for quantitative analysis
and uncertainty determination. Otherwise the model is not valid, i.e. param-
eters act on the response with higher complexity than those introduced in the
matrix effect. For this calibration, the validity test gives:
Model FOBS Fν1,ν2(0.95) Result
1.WIC FOBS(1.WIC) = 80.9 F4,24(0.95) = 2.78 not valid
1.WOC FOBS(1.WOC) = 78.6 F5,24(0.95) = 2.62 not valid
2.WIC FOBS(2.WIC) = 23.4 F3,24(0.95) = 3.01 not valid
2.WOC FOBS(2.WOC) = 20.2 F4,24(0.95) = 2.78 not valid
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4.4.4.2 Quantification procedure
For the quantification, the response of an aliquot was measured n = 6 times by
HPLC giving an average ratio Y. According to 1.WOC model, the corresponding
DBF concentration [DBF] was calculated with the corresponding uncertainties
using the relations:
[DBF ] = Y
B1.WOC
(4.17)
And
δ[DBF ] = Sr(1.WOC) · t5(0.95)
B1.WOC
·
√
1
N
+ 1
n
+ (Y − YSCi)
2
N ·B21.WOC ·Var([Gly − Fmoc]SCi)
(4.18)
4.4.4.2.a DBF quantification
For the quantification, 1 ml of solution SA1 and 100 µl of the collected aliquots
from the reaction solution were mixed, diluted to 10 ml with NMP and analyzed
by HPLC. Using the signal from the 6 samples, a relative ratio Y = 0.45563 was
found.
The calibration curve gives [DBF] = 20.6864 ± 0.320463 µM which cor-
responds to the amount of DBF released by Fmoc degradation. As a conse-
quence, the estimated amount of PL1 coupled to 5ChipM in 10 ml of NMP is
20.6864 µmol.
4.4.5 PL2 coupling on ChipM
To a solution of DIPEA and PL2 in 8 ml of NMP, were added 5
( 2
LA|40
)·ChipM
(experiment C, Chapter 3). The solution was gently shaken at 50 ℃ during
15 minutes before adding HBTU and HOBt dissolved in 2 ml of NMP.
After one hour of reaction, the
( 2
LA|40
)·ChipM·PL2 were submitted to three
washes with a 5%(v:v) DIPEA/NMP mixture.
Amount Mw(g·mol−1)
Concentra-
tion CAS
DIPEA 259.7 mg 129.2432 200.93 mM 7087-68-5
HBTU 568.8 mg 379.2418 149.98 mM 94790-37-1
HOBt 203.0 mg 135.1234 150.23 mM 123333-53-9
NMP 10.0 ml — — 872-50-4
PL2 149.6 mg 299.2765 49.98 mM 175281-76-2
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4.4.6 Acetylation of ChipM
To a solution of Ac2O and DIPEA in NMP, were added 5ChipM (experiment
B, Chapter 3). The solution was gently shaken at room temperature. After
30 minutes of reaction, the ChipM·AcO were submitted to three washes with
a 5%(v:v) DIPEA/NMP mixture.
Amount Mw(g·mol−1)
Concentra-
tion CAS
Ac2O 2.0 ml 102.0886 2119.72 mM 108-24-7
DIPEA 0.5 ml 129.2432 287.05 mM 7087-68-5
NMP 7.5 ml — — 872-50-4
4.4.7 Ibuprofen coupling on ChipM PL2
4
( 2
LA|40
)·ChipM·PL2 were added to a solution of DMAP and ibuprofene in
6 ml of NMP. The solution was gently shaken at 50 ℃ during 15 minutes before
adding DIC and HOBt dissolved in 2 ml of NMP. After 24 hours of reaction,
the
( 2
LA|40
)·ChipM·PL2·(Ibu) were submitted to three washes with a 5%(v:v)
DIPEA/NMP mixture.
Amount Mw(g·mol−1)
Concentra-
tion CAS
DIC 189.4 mg 126.1995 150.07 mM 693-13-0
DMAP 6.2 mg 122.1677 5.07 mM 1122-58-3
HOBt 203.0 mg 135.1234 150.23 mM 123333-53-9
Ibu 102.6 mg 206.2808 49.73 mM 15687-27-1
NMP 8.0 ml — — 872-50-4
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Chapter 5
Transdermal release
Abstract: The aim of this chapter is to demonstrate the proof of concept for the
ATTS. The proof of concept consists in the significant release of ibuprofen and
its diffusion through human skin epidermis while the drug loaded photosensitive
matrix is exposed to UV light. This study demonstrates that is is possible to
produce a support able to reach the requirement for transdermal delivery to
human skin. Photo-induced release opens the way to several applications as it
makes a precise and tuned control of drug release possible to individual patient
treatment by a simple programming of the UV emission.
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5.1 General remarks
The in-vitro studies of drug permeation through the skin are the most used
techniques for skin formulations such as TTS. Several techniques are available
to test the efficiency of a transdermal formulation. However, the choice of the
method depends of the substance studied and the formulation applied to the
skin. Among different equipments, the most widespread remain the Franz dif-
fusion cell (FD-C) and the Saarbrücken penetration model (SB-M) [1].
The FD-C (Figure 5.1) study involves the diffusion measurements of sub-
stances through the skin, or skin like membrane, to a receiving solution (RS)
assembled in a diffusion cell in function of time. In that case, the formulation
is placed in a donor chamber and separated from a receptor compartment by a
membrane which can be natural or synthetic.
The receptor usually contains a buffer solution that mimics physiological con-
ditions [2,3] and the system is maintained at constant temperature to simulate
the skin temperature [1,4,5]. Constant stirring of the receptor compartment en-
sures the diffusion of the drug by homogenization of the RS. Finally, a sampling
is performed either in a continuous form or at pre-determined times intervals [6]
for quantification.
Donor chamber
Skin membrane
Receptor chamber
Side arm
Clamp
Magnetic stirrer
Figure 5.1: Schematic representation of a static FD-C system
5.2 Strategy
According to the recommendations of the Organization for Organisation for
Economic Co-operation and Development (OECD) concerning the transdermal
studies, the use of real skin instead of reconstructed skin is preferred as they
do not exhibit the same barrier properties (OECD test guideline 428). As a
consequence, this study was conducted using real human skin sample. However,
considering the important thickness of the dermis layer, the proof of concept
was established using only the epidermis [4].
In this study, the ibuprofen modified support is placed into the donor cham-
ber and the full system is irradiated at λ = 365 nm. Once the matrix is activated
by the light the photocleavable linker releases the ibuprofen which is quantified
by HPLC. For the proof of concept,
( 2
LA|40
)·ChipM·PL2·(Ibu), used as mS,
were exposed to UV light and the ibuprofen released through human epidermis
or in RS was quantified.
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5.3 Results and discussion
5.3.1 Human epidermis preparation
Several methods exist for the separation of the dermal layers among the en-
zymatic separation with dispase [7,8,9], mechanical methods using a dermatome
able to cut thin layers of skin, thermal separation by heating of the skin at 60℃
during 90 secondes [4].
Figure 5.2: Human epidermis sample (scale bar 10 mm)
Red circle: non usable parts ; Black circle: used parts
For this study, the separation protocol was given by the skin supplier and is
based on lysis to denature cells at the dermis/epidermis interface. This method
is very efficient and allows to isolate the epidermis from large surface skin sam-
ples (Figure 5.2).
It should be noticed that the obtained epidermis surface represents 130% of
the initial sample surface due to important skin invaginations. This means that
the real skin surface exposed to aChipM during drug release is certainly higher
that what is observed in this transdermal study since the surface of exchange is
larger than the surface of aChipM.
5.3.2 In-vitro permeation study
The ibuprofen release study from
( 2
LA|40
)·ChipM·PL2·(Ibu) is divided into two
parts. In a first time, the release was realized in solution to characterize quan-
titatively the release under UV light.
In a second time, the release was triggered under the same conditions but the
quantification was investigated after diffusion of ibuprofen through an epidermis
sample using a FD-C.
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5.3.2.1 ChipM preparation
While released from the , the pores represent the only pathway for the ibuprofen
to leave the structure. As a consequence, the liquid filling the pores is of major
importance in the release. Moreover, its characteristics directly influence the
drug solubility, skin acceptability or kinetic of the release.
The dM is the continuous liquid phase that allows the drug diffusion in the
ChipM. In this study, a 10 mM Sørensen’s buffer is used as dM model and
its implementation into the pores was obtained by repeated soakings in buffer.
According to the nomenclature (Appendix C), the obtainedChipM are called( 2
LA|40
)·ChipM·PL2·(Ibu)·{Sø}.
5.3.2.2 Release
The FD-C experiment was carried out using epidermis positioned between the
donor and acceptor chamber while the free release experiment was conducted
by immersing directly theChipM in RS.
In both cases a negative control was performed by keeping one drug loaded
ChipM protected from light. The RS was made of VRS = 8.0 ml of a 10 mM
Sørensen’s buffer, at pH = 7.4, and was stirred with a magnetic bar at 500 rpm.
At pre-determined time intervals, aliquots of Va = 500 µl were collected
from RS and replaced immediately with the same volume of buffer. Samples
were collected during 24 hours and analyzed by HPLC.
After only 10 minutes, a clear color change appears on ChipM submitted
to UV light, while the negative controls remained unchanged. After 24 hours of
illumination, the difference is even more noticeable (Figure 5.3).
A B
Figure 5.3: ChipM after 24 hours of experiment
A: Negative control ; B: Exposed to UV light
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This color change can be explained by the conversion of the aromatic center
of the photolinker from an o-nitrobenzyl ether to an o-nitrosobenzaldehyde [10,11].
5.3.2.2.a Calibration
A special attention was carried in the treatment of the data as the ChipM
production (Chapter 3) is not optimized. Moreover, as the volume VRS = 8 ml
is important, a highly precise method was essential for ibuprofen quantification.
Since the proof of concept is considered as established by the obtaining of
significant ibuprofen release under UV light, the calibration was realized using
the method developed in Chapter 4. By applying this method to the calibration
of ibuprofen, the calculations reveal that a linear model (1.WOC) reached the
quality required for a precise quantification.
5.3.2.2.b Ibuprofen quantification
The release experiment shows a significant release of ibuprofen for theChipM
exposed to UV while the negative control, without activation of the photolinker,
confirms the absence of release (Figure 5.4).
By comparing the evolution of the ibuprofen concentration in RS for the two
experiments, a very clear difference is observed. Indeed, for the free release in
solution (Figure 5.4, Left), the time necessary to observe a significant release is
short (about 30 minutes for ∼ 9.7 µg) but is close to 300 minutes for the release
of ∼ 7.6 µg through the epidermis (Figure 5.4, Right).
Figure 5.4: Cumulated ibuprofen released from loadedChipM
Left: Free release in solution ; Right: Release through human epidermis
Moreover, it can be noticed that in both cases the released amount does not
exceed 100 µg·ChipM−1. An optimization of the production process should
considerably improve this result as the theoretical coupling is approximately
of 0.35 mmol·g−1 of chitosan [12,13], giving ∼ 1.7 mg for a 28 mm in diameter
ChipM.
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5.3.3 Mathematical model of ibuprofen release
In order to describe the release of ibuprofen fromChipM a mathematical model
based on kinetic equations instead of Fick’s law was developed. Results for the
free release and release through the epidermis (Figure 5.5) show interesting cor-
relations with the experimental data.
Indeed, the obtained values gave ibu0 = 60 µg·ChipM−1, as the amount of
ibuprofen immobilized, and kinetics constants k1 = 0.01066 for photocleavage,
k2 = 0.00711 for diffusion in dM and k3 = 0.00063 for diffusion into epidermis.
It clearly appears that the release is affected by the diffusion into the epi-
dermis which is in accordance with the observations for drug diffusion into the
skin [4].
Figure 5.5: Estimated cumulated ibuprofen released
from loadedChipM using model
Left: Free release in solution ; Right: Release though human epidermis
In terms of production, this model shows that the release can be controlled
not only by modifying the time of illumination of the photosensitive ChipM
but also by adapting parameters to play on each kinetics. As an example, below
are listed some of the parameters able to influence the release kinetics of a drug.
[ibu]ChipMt influenced by:
• Photolinker: cleavage wavelength, sensitivity ;
• ChipM: loading, light diffraction, diffusion, evanescence and reflection
(possibility to add doping agents to theChipM) ;
• dM: interactions with the photocleavage reaction rate, pH, light diffrac-
tion, etc. (same thanChipM).
[ibu]dMt influenced by:
• ChipM: porosity, pore size, mechanical properties ;
• dM: viscosity, pH, physico-chemical interactions with drug molecules.
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[ibu]epit influenced by:
• dM: pH, physico-chemical interactions with the skin (possibility to add
permeation enhancers) ;
• Drug: physico-chemical interactions with the skin (possibility to use drug
carriers).
5.4 Experimental section
5.4.1 General materials and methods
Three buffers were used to conduct this study. Two of them (Sørensen’s buffers)
were used for the establishment of the ibuprofen calibration curve, as dM in drug
loaded matrices and as RS. The third one (McIlvaine’s buffer) was used in the
HPLC procedure.
5.4.1.1 Chemicals
ACN: CHROMASOLV® gradient grade, for HPLC, ≥ 99% ; Citric acid: ACS
reagent, ≥ 99.5% ; EDTA: BioUltra, anhydrous, ≥ 99% (titration) ; Ibu: ≥ 98%
(GC) ; Isopropanol: BioReagent, for molecular biology, ≥ 99.5% ;
NaH2PO4: BioReagent, for molecular biology, anhydrous, ≥ 98% ;
NaH2PO4·2H2O: BioUltra, for molecular biology, ≥ 99.0% (T) ; PMSF: ≥ 99.9%
(T) (Sigma-Aldrich Chemie GmbH, Buchs, CH) were used as received. Milli-Q
water with resistivity of more than 18.2 MΩ·cm was provided by a Millipore
Milli-Q filtering system with filtration through a 0.22 µm Millipak filter.
5.4.1.2 Skin sample
Excised human skin from Caucasian patient (Genoskin, Toulouse, FR) who had
undergone abdominal surgery was received frozen after being decontaminated
and tested for HIV/AIDS 1/2, B and C hepatitis.
5.4.1.3 Franz diffusion cells
The diffusion experiments were performed in FD-C (diffusion area 1.77 cm2,
acceptor volume 10 ml) and in glass containers for the free release. In order to
compare results from free release and release on FD-C, the experiments were
both conducted at 39 ℃ using 10 mM Sørensen’s buffer as RS. In both cases
aliquots having a volume of Va = 500 µl were taken out regularly from the RS
and replaced with buffer to keep the volume constant [14].
5.4.1.4 Characterization
Chromatography was carried using an Agilent 1100 series HPLC instrument
equipped with a high pressure gradient pump, an auto-injector set at 100 µl
and a UV-Visible detector set at λ = 238 nm. The separations were carried
out on a 5 µm Sphereclone ODS (2) column (Phenomex, 150 mm x 4.60 mm
i.d.) at 40℃ and eluted at 1.5 ml·min−1 (pressure ∼ 73 bars) using an isocratic
mixture of 55% ACN and 45% McIllvaine’s buffer [14]. The column was coupled
to a security guard cartridge system.
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The signal measurements were obtained by integrating the peak area of the
ibuprofen absorbance signal after baseline correction on the IGOR-Pro software.
The limit integration interval [3.60;4.22] min was determined by differentiation
of the signal curve. Using this method, the blank retention time is t0 = 0.85 min
and the retention time for ibuprofen is tibu = 3.05 min.
5.4.2 Buffers preparation
5.4.2.1 25 mM Sørensen’s buffer pH 7.4
The 25 mM Sørensen’s buffer was prepared by dissolving 3.0 g of NaH2PO4 in
900 ml of water. The pH of the solution was adjusted to pH = 7.42 before being
diluted to one liter, giving a final buffer with pH = 7.4.
Amount Mw(g·mol−1)
Concentra-
tion CAS
NaH2PO4 3.0 g·l−1 119.9770 25 mM 7558-80-7
5.4.2.2 10 mM Sørensen’s buffer pH 7.4
The 10 mM Sørensen’s buffer was prepared by dissolving 1.2 g of NaH2PO4in
900 ml of water. The pH of the solution was adjusted to pH = 7.42 before being
diluted to one liter, giving a final buffer with pH = 7.4.
Amount Mw(g·mol−1)
Concentra-
tion CAS
NaH2PO4 1.2 g·l−1 119.9770 10 mM 7558-80-7
5.4.2.3 100 mM McIlvaine’s buffer pH 2.2
The 100 mM McIlvaine’s buffer pH = 2.2 is usually obtained by mixing 980 ml
of a 100 mM citric acid solution and 20 ml of 200 mM NaH2PO4·2H2O solu-
tion [15]. Instead of this, the buffer was prepared by dissolving the corresponding
amount of NaH2PO4·2H2O and citric acid in 1 l of water and the pH adjusted
to pH = 2.2.
Amount Mw(g·mol−1)
Concentra-
tion CAS
Citric acid 18.8281 g·l−1 192.1235 ∼ 98 mM 77-92-9
Na2HPO4·
2H2O
0.7119 g·l−1 117.9894 ∼ 4 mM 10028-24-7
5.4.3 Skin preparation
The separation of the dermis from the epidermis was realized by immersing the
thawed skin in a dedicated solution according to a procedure given by the skin
supplier.
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This solution was obtained by mixing 10 ml of a 50 mM EDTA solution
(in 10 mM Sørensen’s buffer, pH adjusted to pH = 8 with NaOH), 500 µl of a
100 mM PMSF (in isopropanol) and 90 ml of a 10 mM Sørensen’s buffer at 56℃
during 15 minutes. The skin was then washed in 100 ml of 10 mM Sørensen’s
buffer at 4 ℃ during 5 minutes. The epidermis layer was peeled carefully from
the dermis using a flat tweezer and washed several times with buffer. Finally,
epidermis disks (Øepi = 28 mm) were punched out from epidermis and pre-
hydrated in buffer at 4 ℃ during one hour prior to use.
Amount Mw(g·mol−1)
Concentra-
tion CAS
EDTA 730.6 mg in50 ml 292.2426 50 mM 60-00-4
PMSF 174.2 mg in10 ml 174.1927 100 mM 329-98-6
5.4.4 Permeation experiment
5
( 2
LA|40
)·ChipM·PL2·(Ibu) with ØChipM = 28 mm, were used (Chapter 3,
experiment C for
( 2
LA|40
)·ChipM production, Chapter 4 for surface immobi-
lization conditions).
5.4.4.1 ChipM preparation
The implementation of the dM in theChipM was realized by soaking the drug
loaded porous structures during 20 minutes in the 10 mM Sørensen’s buffer.
This exchange was repeated three times with 5 ml of buffer perChipM.
5.4.4.2 Release procedure
5.4.4.2.a Release on Franz diffusion cells
3
( 2
LA|40
)·ChipM·PL2·(Ibu)·{Sø} were used for this experiment. The assembly
of the FD-C was made by placing the epidermis onto the FD-C with the SC side
facing theChipM porous side and the dermal side in contact with the RS [16].
The system was maintained by a plastic support and screwed to assure tight
junction. The donor compartment was finally sealed with a transparent plastic
foil while the receptor chamber was filled with VRS = 8 ml of 10 mM Sørensen’s
buffer using the side arm of the FD-C.
Two equipped FD-C were placed in a UV box (CL-1000 Ultraviolet crosslinker
UVP, 1 mJ·cm−1). The third one was kept protected from light and used as a
negative control.
5.4.4.2.b Free release in solution
2
( 2
LA|40
)·ChipM·PL2·(Ibu)·{Sø} were used for the free release experiment.
They were immersed in VRS = 8 ml of 10 mM Sørensen’s buffer and the con-
tainer sealed with a plastic foil. One was placed in the UV box while the second
one was kept protected from light and used as a negative control.
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5.4.5 Quantification
5.4.5.1 Calibration procedure
5.4.5.1.a Standard solutions
Stock solutions
To reduce uncertainties due to the measurement of low mass and speed-up
the dissolution of ibuprofen, a concentrated ibuprofen stock solutions S0 was
prepared using the 25 mM Sørensen’s buffer before being diluted to give S1.
For the preparation of S0, ibuprofen was let to dissolve 24 hours protected from
light at room temperature under stirring.
S0
50.0 mg of ibuprofen in [ibu]S0 = 0.25 mg·ml−1
200 ml of 25 mM in 25 mM
Sørensen’s buffer Sørensen’s buffer
S1
10.0 ml of S0 diluted to [ibu]S1 = 0.1 mg·ml−1
25 ml with in 10 mM
pure water Sørensen’s buffer
Calibration solutions
A series of N = 6 calibration solutions SC i were prepared using increasing vol-
umes VS1 i of stock solution S1 and diluted to 10 ml with the 10 mM Sørensen’s
buffer.
— VS1 → SC i [ibu]SCi
SC1 0.00 ml [ibu]SC1 = 0.00 µg·ml−1
SC2 0.75 ml [ibu]SC2 = 7.50 µg·ml−1
SC3 1.00 ml [ibu]SC3 = 10.0 µg·ml−1
SC4 1.50 ml [ibu]SC4 = 15.0 µg·ml−1
SC5 2.00 ml [ibu]SC5 = 20.0 µg·ml−1
SC6 2.50 ml [ibu]SC6 = 25.0 µg·ml−1
Once prepared, calibration solutions were stored at room temperature in the
dark prior to analysis.
5.4.5.1.b Calculations
Using the method developed in Chapter 4 the analysis were conducted 5 times
(p = 5) for each of the N standard solutions.
Pearson product-moment correlation coefficient
The Pearson correlation coefficient of this calibration is ρ2 = 0.998921 proving
a good correlation between the ibuprofen concentration in calibration solutions
and the absorbance signal.
96
ALTHERAS Chapter 5
Homoscedasticity
The Bartlett’s test gives χ2OBS = 2.5 < χ25 = 11.1 proving that the calibration
method is homoscedastic. As a consequence, the N standard deviations were
merged in S0 = 16.16385510 with a degree of freedom ν0 = 24.
Regression parameters
The regressions models for this calibration are:
For 1.WIC:
Y = 64.73263358·X + 0.74581964401
For 1.WOC:
Y = 64.77373653·X
For 2.WIC:
Y = 23.90637051·X2 + 58.40165929·X + 0.2500888374
For 2.WOC:
Y = 61.65434390·X2 + 0.1543404903·X
Significance of coefficients
The significance of the coefficients study gives:
Model tN−k−1(0.95) tOBS(0.95) Result
1.WIC t4(0.95) = 2.776
tOBS(B1.WIC) = 60.86 significant
tOBS(A1.WIC) = 0.04 not significant
1.WOC t5(0.95) = 2.571 tOBS(B1.WOC) = 126.81 significant
2.WIC t3(0.95) = 3.182
tOBS(C2.WIC) = 4.25 significant
tOBS(B2.WIC) = 37.47 significant
tOBS(A2.WIC) = 2.67 not significant
2.WOC t4(0.95) = 2.776
tOBS(C2.WOC) = 2.07 not significant
tOBS(B2.WOC) = 39.71 significant
This reveals that only the 1.WOC coefficients are all significant.
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Models validity
The validity of the models was finally tested, giving:
Model FOBS Fν1,ν2(0.95) Result
1.WIC FOBS(1.WIC) = 1.75 F4,24(0.95) = 2.78 valid
1.WOC FOBS(1.WOC) = 1.40 F5,24(0.95) = 2.62 valid
2.WIC FOBS(2.WIC) = 0.33 F3,24(0.95) = 3.01 valid
2.WOC FOBS(2.WOC) = 0.84 F4,24(0.95) = 2.78 valid
The 4 models are valid. However, considering the significance of coefficients,
only the 1.WOC model can be used for the quantification of the ibuprofen
release.
5.4.5.2 Quantification procedure
5.4.5.2.a Ibuprofen concentration in the aliquot
For the quantification, the response of each aliquot was measured n = 6 times by
HPLC, giving an average signal Yi. According to the 1.WOC model, the corre-
sponding ibuprofen concentration [ibu]i was calculated with the corresponding
uncertainties δ[ibu]i using the relations:
[ibu]i =
Yi
B1.WOC
(5.1)
And
δ[ibu]i =
Sr(1.WOC) · t5(0.95)
B1.WOC
·
√
1
N
+ 1
n
+ (Y − YSCi)
2
N ·B21.WOC ·Var([ibu]Sci)
(5.2)
5.4.5.2.b Cumulated ibuprofen release
The cumulated ibuprofen amount released mibui is defined as the sum of the
ibuprofen amount in the cell plus the amount of ibuprofen removed after each
sampling:
mibui = VRS [ibu]i + Va
i−1∑
j=1
[ibu]j (5.3)
The corresponding uncertainties were obtained by using the law of uncer-
tainties propagation:
∆mibui =
√√√√ i∑
j=1
∣∣∣∣∂mibui∂[ibu]j
∣∣∣∣2 |δ[ibu]j |2 (5.4)
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5.4.6 Mathematical model
5.4.6.1 Problem description
The transport of drug in a membrane is governed by the Fick’s second law of
diffusion. In this study, the diffusion can be described by working with three
diffusion domains which are the dM, the epidermis and the RS. The free re-
lease in solution is the same but without the epidermis domain. On the same
time, the ibuprofen introduction in the dM is imposed by UV-induced photo-
cleavage reaction that is considered arbitrarily as a first oder kinetic reaction [17].
In one dimension, this mathematical representation gives a system of partial
differential equations (PDE) that describes the ibuprofen concentration profile
in each domain in function of the drug release from theChipM.
d[ibu]t
dt
= −kA [ibu]t x = 0
∂[ibu]x,t
∂t
= Dibu.dM
∂2[ibu]x,t
∂x2
x ∈ dM
∂[ibu]x,t
∂t
= Dibu.epi
∂2[ibu]x,t
∂x2
x ∈ epidermis
∂[ibu]x,t
∂t
= Dibu.RS
∂2[ibu]x,t
∂x2
x ∈ RS
(5.5)
With Dibu.y the diffusion coefficient of ibuprofen in the domain y. Its value,
expressed in m2·s−1, depends on the temperature of the diffusion layer y and
on ibuprofen characteristics. However, the collecting of information describing
the photocleavage characteristics from ChipM, the diffusion of the ibuprofen
through a complex porous structure, the influence of dM and RS characteristics
(viscosity, interactions with ibuprofen), etc. appeared difficult.
As a consequence, the model proposed only considers the kinetic aspect and
not the spatial dimension. This approximation means an isotropic distribution
of ibuprofen in each domain of the system:
∂[ibu]x,t
∂x
= 0 (5.6)
However, by working with this condition, the Fick’s equations cannot be
solved. For this reason, the model developed is based on an analogy between
diffusion phenomenon and chemical reaction kinetic equations.
5.4.6.2 Model proposal
The analogy proposed compares the passage of the ibuprofen between domains
to a chemical reaction (Table 5.1). In a chemical reaction a substance A is
converted to B and the kinetic of the reaction is characterized by a constant ka.
Considering a linear multistage reaction, B gives C which is finally transformed
into D with the corresponding kinetic constants kb and kc.
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Kinetic A B C D
ka kb kc
Diffusion
model ibuChipM ibudM ibuepi ibuRS
k1 k2 k3
Table 5.1: Model Proposal
The release of ibuprofen from the surface of the pores into the dM is a pho-
tochemical reaction. In this model the same equations are applied to describe
the passage of the ibuprofen from the dM to the epidermis and from the epider-
mis to the RS. As a consequence the ibuprofen bound toChipM (ibuChipM ) is
converted to ibudM which gives ibuepi and finally ibuRS , with the corresponding
constants k1, k2 and k3.
Thus, by assuming only first order kinetic reactions, the system of equation
becomes:

d[ibu]ChipMt
dt
= −k1 [ibu]ChipMt onChipM surface
d[ibu]dMt
dt
= k1 [ibu]ChipMt − k2 [ibu]dMt in dM
d[ibu]epit
dt
= k2 [ibu]dMt − k2 [ibu]epit in epidermis
(5.7)
With

[ibu]ChipMt=0 = ibu0
[ibu]dMt=0 = 0
[ibu]epit=0 = 0
(5.8)
The resolution of this system gives:

[ibu]ChipMt = ibu0 e−k1 t
[ibu]dMt =
ibu0 k1
k2 − k1
(
e−k1 t − e−k2 t)
[ibu]epit =
ibu0 k1 k2
k2 − k1
(
(e−k1 t − e−k3 t)
k3 − k1 −
(e−k2 t − e−k3 t)
k3 − k2
)
(5.9)
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Finally, the amount of ibuprofen released freely in solution is estimated by
the equation [ibu]RSt = ibu0 – [ibu]
ChipM
t – [ibu]dMt since the ibuprofen does not
cross the epidermis layer. In that case an accumulation of ibuprofen in RS is
observed.
With the passage through the skin, the ibuprofen is first transferred from
the ChipM to the , then through the epidermis to RS. In that case too an
accumulation of the ibuprofen in RS should be observed. However, the low
permeability of the epidermis should delay this accumulation compared to the
free release in solution.
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Chapter 6
Prospectives for design and
programming
Abstract: This last part is dedicated to the practical applications of the ATTS
and includes proposals and potential uses. For this reasons, this chapter rep-
resents a substantial document for future studies as it concerns the design of
the system but also the programming of the electronic support. Finally, it an-
swers to the main specifications introduced at the beginning of this study by
the creation of a tool which makes chronotherapies and polytherapies possible.
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6.1 General remarks
The use of the intelligent transdermal technology proposed is based on time and
power modulation ofChipM illumination and on the programming of an eS as
the released amount is function of this illumination time.
Indeed, the eS contains a program which allows the control of illumination
on different areas but also the control of moment and illumination time of the
mS. This opens the way to personalized treatment by implementing polythera-
pies and chronotherapies on a single support. However, since the initial design
of the ATTS is composed of mS embedded in an aS, several possibilities of de-
sign exist and deeper investigations are required. For these reasons a range of
applications able to broaden the capacities of release were identified. Further-
more, to limit the cost of production resulting from personalized medications,
the product described is an assembly based on a mosaic principle. This allows,
from regular mass products, to obtain highly individualized assemblies.
As a consequence, the ATTS is made of detachable items. The items are
assembled on an aS which combines everything together. Once the mS is empty,
or the energy supply is finished, the part can be replaced, extending the life time
of the device thus reducing the cost for the patient.
6.2 ATTS as tool for polytherapy
In a near future, the use of polytherapies may increase in a significant way.
However, the lack of tools allowing a rigorous control of administration cur-
rently limits their use. Therefore, the ATTS developed represents an innovative
solution to manage the release of several drugs from a single support.
6.2.1 Mode of use
Because of their structure, the ChipM, modified or not, can be used in differ-
ent ways. In case of non modified structures, the matrices can complete the
outfit of the existing passive TTS since the release of a medication happens by
uncontrolled diffusion. On the contrary, the modified matrices can serve as a
powerful tool to ameliorate the available devices.
Moreover, since the ATTS mS is based on the use of a porous structure,
the diffusion phenomenon is really fast compared to a traditional TTS since the
released molecules diffuse in liquid dM.
6.2.1.1 Passive use
The use of the patch in passive mode means that the release happens without
control. This is the case for all the ChipM which do not have secondary cou-
plings. Passive uses are presented here (Figure 6.1) to demonstrate potential
uses of the the ATTS. In A, the ChipM is loaded with a basic dM such as
a buffer solution. This kind of structure can be used as protective or wound
healing. Indeed, if the initial ChipM is mainly dedicated to be used as a mS,
the opposite can also be imagined with its use as a trap, for example for physi-
ological liquids after injury.
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A B C D
E F G H
Figure 6.1: ChipM for use in passive mode
A:ChipM empty ; B: Drug loaded dM ;
C: Primary coupling onChipM ; D: DopedChipM ;
E, F, G, H: Combinations of A, B, C and D
Based on the same idea, the loading of the dM with an active molecule is
presented in the matrix B. This active molecule is released without control and
can be used to neutralize absorbed products. In release mode, this is a classical
passive TTS. The matrix C, represents aChipM whose surface has been modi-
fied by a primary coupling. This modification can help to stabilize the chitosan
or, as for the matrix B, to neutralize absorbed molecules. In D, is presented
a doped ChipM in which substances are incorporated in the structure of the
material, here the chitosan. These agents can serve to improve the aesthetic
appearance of the product but also to increase the mechanical properties. Ma-
trices E, F, G and H are combinations of the previously described A, B, C and
D.
6.2.1.2 Active use
The use of the ChipM in an active way depends of the presence of a stimuli
responsive moiety as primary coupling. Indeed, as it is demonstrated in this
study a controlled release is possible by submitting a photosensitiveChipM to
light. Herein are proposed different possibilities of active uses with a photolinker
as primary coupling (Figure 6.2).
A B
C D
Figure 6.2: ChipM for use in active mode
A: Secondary coupling onChipM ; B: Secondary coupling with drug loaded dM ;
C: Secondary coupling with dopedChipM ; D: Combination of B and C.
In A, an active agent is immobilized on a photolabile moiety and released
while subjected to light. This corresponds to the structure used to demonstrate
the proof of concept of the ATTS in Chapter 5. In B, the dM is loaded with an
agent and released from theChipM without control.
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This free agent can be another drug, a permeation enhancer, a molecule
able to reduce skin irritation, an ionic substance to improve the release rate by
increasing the gradient, etc. In that case, the obtained TTS is both active and
passive. This gives the possibility to indirectly control the release by working
with highly concentrated drug loaded dM, the tuning is assured by controlled
release of a permeation enhancer bound to the photolinker.
The matrix C is a dopedChipM. As for the doped matrix in passive mode,
it can serve to modify the ChipM properties or appearance. However, in the
case of photorelease, the doping also makes it possible to modify the response of
the matrix to the light. Finally, in D, theChipM is a mix of the three others.
6.2.2 Architecture
In addition to the mode of action, the design of the final ATTS is also as a
way to personalize a treatment. For this reason, different architectures are
suggested using a circular design. For each of the architecture investigated the
theoretical drug loading using the values obtained in Chapter 4 were calculated
and compared with commercially available products.
6.2.2.1 Patchwork geometry
For the architectures it is possible to use several mS on the same aS, each of
them facing one LED (Figure 6.3). The architecture α7 can be used for example
as a “weekly TTS” with the release from one mS per day. This method presents
the advantage to makes it possible the use of several independent mS loaded
with different drugs.
α1 α2 α3 α4
α5 α6 α7
Figure 6.3: Architecture α1 to α7, mS in blue, aS in orange
As a consequence it induces a reduction of the production costs with the
possibility to tune the ATTS by placing different mS. Moreover, this opens the
way to reusable TTS since only the aS and the mS have to be replaced regularly,
the eS remaining the same between usages.
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6.2.2.2 Combinations of mS
Considering an industrial production of j different mS and using the architec-
tures introduced previously, the amount of combinations that are possible to
obtain for each architecture can be calculated by using the relation 6.1.
ℵ(αi; j) =
i∑
k=1
(
i− 1
k − 1
)(
j
k
)
= Γ(i+ j)Γ(j) Γ(i+ 1) (6.1)
With Γ(n) = (n− 1)! (6.2)
Until j = 7, the amount of combinations are listed in the table 6.1.
α1 α2 α3 α4 α5 α6 α7
j = 1 1 1 1 1 1 1 1
j = 2 2 3 4 5 6 7 8
j = 3 3 6 10 15 21 28 36
j = 4 4 10 20 35 56 84 120
j = 5 5 15 35 70 126 210 330
j = 6 6 21 56 126 252 462 792
j = 7 7 28 84 210 462 924 1716
Table 6.1: Combinations for ATTS architectures
The results clearly show the potential of the ATTS since the production of 7
different mS allows the assembly of 1716 different TTS by using the architecture
α7.
As an other example, if 18 different mS are commercially available, by using
the architecture α5, the potential combinations are ℵ(α5; 18) = 26,334. The
resort to biosimulation is a clear advantage for the study of interactions resulting
from these combinations.
6.2.2.3 Theoretical drug loading
According to the geometric specifications of the project, the diameter of the
aS is limited to the width of a credit card (5.398 cm from ISO/IEC 7810 ID-1
standard standard).
By working with a 1.988 cm thick mS and a drug loading of 168.99 µmol·g−1
of chitosan (Chapter 4), a surface loading of 0.6719 µmol·cm−2 can be reached.
Using this value, the theoretical loading for each of the architectures was esti-
mated.
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6.2.2.3.a Architecture α1
Unit mS
radius 2.699 cm
Surface
density 1.000
Unit mS
surface 22.885 cm
2 Total mS
surface 22.885 cm
2
Unit mS
volume 4.549 cm
3 Total mS
volume 4.549 cm
3
Unit chitosan
mass 90.986 mg
Total chitosan
mass 90.986 mg
Unit mS
loading 15.376 µmol
Total mS
loading 15.376 µmol
6.2.2.3.b Architecture α2
Unit mS
radius 1.350 cm
Surface
density 0.500
Unit mS
surface 5.721 cm
2 Total mS
surface 11.443 cm
2
Unit mS
volume 1.137 cm
3 Total mS
volume 2.275 cm
3
Unit chitosan
mass 22.746 mg
Total chitosan
mass 45.493 mg
Unit mS
loading 3.844 µmol
Total mS
loading 7.688 µmol
6.2.2.3.c Architecture α3
Unit mS
radius 1.253 cm
Surface
density 0.646
Unit mS
surface 4.930 cm
2 Total mS
surface 14.788 cm
2
Unit mS
volume 0.980 cm
3 Total mS
volume 2.940 cm
3
Unit chitosan
mass 19.597 mg
Total chitosan
mass 58.792 mg
Unit mS
loading 3.312 µmol
Total mS
loading 9.935 µmol
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6.2.2.3.d Architecture α4
Unit mS
radius 1.118 cm
Surface
density 0.686
Unit mS
surface 3.926 cm
2 Total mS
surface 15.706 cm
2
Unit mS
volume 0.781 cm
3 Total mS
volume 3.122 cm
3
Unit chitosan
mass 15.611 mg
Total chitosan
mass 62.443 mg
Unit mS
loading 2.638 µmol
Total mS
loading 10.552 µmol
6.2.2.3.e Architecture α5
Unit mS
radius 0.999 cm
Surface
density 0.685
Unit mS
surface 3.136 cm
2 Total mS
surface 15.681 cm
2
Unit mS
volume 0.623 cm
3 Total mS
volume 3.117 cm
3
Unit chitosan
mass 12.469 mg
Total chitosan
mass 62.344 mg
Unit mS
loading 2.107 µmol
Total mS
loading 10.536 µmol
6.2.2.3.f Architecture α6
Unit mS
radius 0.900 cm
Surface
density 0.667
Unit mS
surface 2.543 cm
2 Total mS
surface 15.257 cm
2
Unit mS
volume 0.505 cm
3 Total mS
volume 3.033 cm
3
Unit chitosan
mass 10.110 mg
Total chitosan
mass 60.657 mg
Unit mS
loading 1.708 µmol
Total mS
loading 10.250 µmol
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6.2.2.3.g Architecture α7
Unit mS
radius 0.900 cm
Surface
density 0.778
Unit mS
surface 2.543 cm
2 Total mS
surface 17.800 cm
2
Unit mS
volume 0.505 cm
3 Total mS
volume 3.538 cm
3
Unit chitosan
mass 10.110 mg
Total chitosan
mass 70.767 mg
Unit mS
loading 1.708 µmol
Total mS
loading 11.959 µmol
It appears from these calculations that, except the architecture α1, the α7
is the designs which presents the highest coupling capacity as more than 75%
of the surface of the ATTS is occupied by mS.
6.2.2.4 Comparison with existing products
By comparing these values with commercially available passive TTS, calcula-
tions give:
Mylan estradiol
(Mylan)
15.50 cm2
Estradiol (1.94 mg)
Mw = 273.3820 g·mol−1
125.16 µg·cm−2
0.46 µmol·cm−2
< to
ATTS
Catapress TTS
(Boehringer In-
gelheim)
7.00 cm2
Clonidine (5.00 mg)
Mw = 230.0939 g·mol−1
714.29 µg·cm−2
3.10 µmol·cm−2
> to
ATTS
Watson
fentanyl
(Watson)
30.00 cm2
Fentanyl (7.50 mg)
Mw = 336.4705 g·mol−1
250.00 µg·cm−2
0.74 µmol·cm−2
≈ to
ATTS
Comparisons clearly highlight that the ATTS is close to commercial prod-
ucts. However, since the coupling capacity of the ChipM is not optimized
(Chapter 4), higher values are expected.
6.3 ATTS as tool for chronotherapy
6.3.1 Notion of response curve and response time
As introduced in Chapter 5, the release of a compound from a ChipM can be
model as a series of diffusion phenomena after the initial photocleavage reaction.
As a consequence each of theChipM can be characterized by a response curve
and a response time. The response curve is defined as the amount of drug in dM
after the photo triggered release and is function of the amount of drug present
on the support. Since this amount varies with time, the rate of release changes
after each new illumination.
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For this reason, the idea of response curve is introduced as a relation between
the amount that is released in function of the remaining amount and the time
of illumination (Figure 6.4). These curves are determined experimentally as in
Chapter 5, or by in-silico extrapolations.
Figure 6.4: Example of a response curve
Once in the dM, a molecule needs a certain time to reach the circulatory
system of the patient. This time corresponds to the time of response and mainly
depends on the structure of theChipM and the composition of the dM.
For this reason, each ChipM formulation is also characterized by its time
of response. Its value is obtained by mathematical modeling or experimentally.
Finally, using the response curve and the time of response, the amount of drug
administrated to a patient can be estimated.
6.3.2 Programming of the ATTS
A dedicated software can be used to manage the drug release from an ATTS.
After the establishment of the posology, the doctor transfers to the software
three data which are the kind of drug (Figure 6.5a, in that case drugs A, B, E
and I), the amount and the time of administration.
By consultation of a database made of response curves and times of response
for each drug loadedChipM, an algorithm proposes different architectures and
combinations that correspond to the posology (Figure 6.5b).
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(a) Posology according to the
prescription
(b) Estimated release from
response curve
Figure 6.5: Comparison between posology and estimated release
The algorithm predicts the correct time of illumination to release the proper
amount of drug, the energy consumption for the eS and also the correlation with
the posology for each proposition.
After selection of the best proposal by the doctor, the software returns the
distribution of the different drug loadedChipM (Figure 6.6a) and also the time
of illumination of the corresponding LED according to the position of the drug
on the architecture (Figure 6.6b).
(a) Architecture
distribution
(b) Corresponding time
of illumination
Figure 6.6: Relation between the architecture and the programming
The prescription is then transmitted to the pharmacist for the assembling
and the programming of the eS. The programing software tree structure is pre-
sented in figure 6.7.
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Figure 6.7: Example of programming software tree structure for the ATTS
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perspectives –
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In the last years, therapies based on transdermal delivery have extensively
increased their number. This phenomenon can be correlated to two main fac-
tors which are a better match with the patient compliance and the design of
commercially available devices able to control the release kinetics. This thesis
describes a new transdermal drug delivery strategy designing surface modified
porous scaffolds able to control the release of drug. The delivery of drug with
time and dose control is becoming a crucial point in the development of new
therapies for chronic diseases.
Herein photochemistry was chosen as good candidate for the control of the
release and the first step consisted to synthesize a photocleavable traceless linker
to allow the design of a photo induced release device. Then, a polymer matrix
with the associated surface modification chemistry was developed to support
the photolinker. Finally, the proof of concept was demonstrated by the release
of ibuprofen on demand by an in-vitro study on human epidermis.
The Chapter 2 presents the synthesis of the photolinker. The reaction is
considered as efficient as the overall yield is higher than 75%. However, some
improvements are still possible for the recrystallization, so it can be assumed
that it is possible to obtain a better yield by using different parameters. On the
same time further studies should complete the understanding of the cleavage
mechanism and kinetic from a polymer support.
Chapter 3 describes the procedure to obtain highly porous chitosan matrices
using the TIPS method. Modifications of the freezing parameters makes it
possible to influence the structure of the final material. Analysis were conducted
to determine in which extent the freezing properties interfere with the phase
change of the solution.
It appeared that the freezing step is of critical importance since ice crystal
size, shape and distribution are strongly related with material characteristics
such as pores size distribution and interconnection of the pores. However, the
control of the ice crystal morphology is difficult and remains a major chal-
lenge. Investigations revealed that their formation is highly dependent of heat
exchanges and more precisely on the evacuation of the latent heat released in
the solution during the phase change. As a consequence, a mathematical model
based on FEM was proposed to predict the heat exchanges.
With these results, a dedicated apparatus, the POMAP, using Peltier effect
to manage the freezing conditions, has been built and makes it possible to con-
siderably improve the quality of the materials produced by the method. Using
the POMAP, obtainedChipM show a homogeneous structure made of uniform
pores and the reproducibility is better.
In the Chapter 4, an innovative and effective method is presented for the
production of ibuprofen loadedChipM. Using the solid phase peptide synthe-
sis method, different couplings on highly porous chitosan microstructures were
realized. The procedures are particularly of interest as they allow an easy sur-
face modification in a minimum of steps and in one solvent, which is crucial for
reactions on porous materials.
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A first coupling was made with the photolinkers PL1. The use of its pro-
tected equivalent PL1-Fmoc allowed the determination of surface loading by the
quantification of DBF after the deprotection step. The quantitation method
developed allows a really precise estimation of the ChipM coupling capac-
ity. This quantitative study gives encouraging results as a surface loading of
168.99 µmol·g−1 of chitosan could be obtained.
As a consequence the use of the Fmoc protected PL1 photolinker represents
an interesting way to optimize the coupling conditions. Indeed, since the loading
is influenced by several parameters such as the temperature, the concentration
of reagents or the diffusion in the pores, a better control of these factors should
allow a significant improvement of the loading. In a second time, the attachment
of ibuprofen onChipM·PL2 was realized and the obtained matrices were used
to demonstrate the proof of concept.
Finally, the possibility to obtain chitin porous structures by acetylation of
the ChipM was also proved. This opens the way to the production of a new
type of passive TTS by impregnation with a drug loaded solution. This is of
great interest as the release from this kind of system should be faster than in a
classical TTS.
In the Chapter 5 the photo-induced ibuprofen release from drug loaded
ChipM was investigated using FD-C system and human epidermis. Using a
very precise method for the quantification of low concentrations, this study can
be considered as a real success because the proof of concept is established by
significant drug release.
To describe the release from theChipM and its diffusion through the porous
structure and through the skin, a mathematical model is suggested. This model
is based on kinetic equations instead of the Fick’s second law of diffusion. How-
ever, the predicted results are in adequacy with experimental results and it
clearly appears that the skin is the limiting factor for transdermal drug de-
livery. Moreover, the obtaining of diffusion rate curves in a separate way for
transport in and in skin allows a better understanding of molecular diffusion
in complex structures and gives access to information which remain difficult to
obtain experimentally. Considering the similarities between the heat equation
and the Fick’s law, the use of the model developed in Chapter 3 for heat ex-
changes should allows a finer description of the molecular transport involved in
the ATTS.
Finally, the establishment of a drug concentration profile in function of all
the involved parameters, such as the time of illumination, the initial amount of
drug, the viscosity of the and the presence or not of permeation enhancer will
allow the programming of the eS using the curves obtained by study of FD-C
or predictions from the model.
The Chapter 6 describes drug combinations on the ATTS. The resulting
product is a fully personalized system by combining standardized modified ma-
trices. This gives a huge advantage in terms of industrial production as only
normal modified matrices have to be produced. Depending of the needs, the
pharmacist, the doctor or the patient can build their system by combining drug
loaded units.
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The ATTS answers to the specifications proposed in this study. Indeed, it
groups on a single support a tool for polymedication and chronotherapy with a
fine control in time and in quantity of the treatment administered to a patient,
even for a complex mixture. Moreover, the study of synergies, using in-silico
biosimulation, should help to identify new synergies between drugs giving, in
theory, an infinity of drug combinations.
The tools and methods developed in this study are also destined to inter-
esting future applications. In particular the researches are now focused on the
development of the POMAP, with the production of additional modules, and
on the surface modification for the improvement of the drug loading.
As an example of module for the POMAP, the addition of pumps should
increase the production possibilities. In case of liquid pumps, different liquids
can be pumped through the production cell such as solvents (for washing, sur-
face modification, etc.) or biological liquids (for cell culture on the scaffold).
The main advantage of the pump module is that the full production is isolated
from the outside giving a perfect control of the working conditions (tempera-
ture, sterile conditions, anaerobic conditions, etc.). In a first time, the use of a
vacuum pump module should simplify the freeze drying.
The addition of a supercritical CO2 module makes the obtaining of highly
porous structures like, for example silica aerogels, possible. In that case, the
average pore size is too small to support a classical freeze drying and the su-
percritical extraction is the only way to get a dry polymer structure. This also
opens the way to the production of materials with double porosity. As an exam-
ple, aChipM obtained by a normal TIPS method can be used as template for
a sol-gel process. The chitosan template is then removed by dissolution and the
resulting structure is dried with supercritical CO2. This method would allow
the obtaining of highly permeable silica aerogels with two different porosities:
one from the template structure and a second one from the aerogel.
Other modules are also under study, such as tunable PM architectures giving
the possibility to use various molds shapes (curves, spheres, etc.) or to apply
different cooling rates on a single mold to induce different porosities on the same
scaffold. Finally, an electrodeposition module is now under development to al-
low the deposition of metal on a classical polymer scaffold, and the obtaining
of porous metal scaffold.
Concerning the surface modifications, reaction conditions have to be opti-
mized in term of reagents concentrations, temperature and soaking methods in
order to improve the drug loading. However, another way is currently explored
and consists in the use of drug loaded nanoparticles. Using this method the drug
loading of a matrix should be increased to a great extent and the nanoparticle
also acts as permeation enhancer. Another advantage of this method is that
all drug molecules can be used on the same photolinker. Several suggestions
are presented in Appendix C using PLGA nanoparticles as drug carrier. This
increases again the release capacities of the ATTS.
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A.1 Apocycin
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Figure A.1: Apocynin
1H-NMR (200 MHz, DMSO-d6 δ) 2.49 (s, 3H, H9), 3.83 (s, 3H, H7), 6.88
(d, J = 8.2 Hz, 1H, H1), 7.45 (d, J = 2.0 Hz, 1H, H4), 7.51 (dd, J = 8.2 Hz,
J = 2.0 Hz, 1H, H2), 9.97 (s, 1H, OH).
13C-NMR (200 MHz, DMSO-d6 δ) 26.15 (C9), 55.57 (C7), 111.15 (C4),
114.86 (C1), 123.33 (C2), 128.86 (C3), 147.46 (C6), 151.65 (C5), 151.65 (C8).
A.2 Ethyl-4-bromobutyrate
Br
6
5
4
3
O
O
2
1
Figure A.2: Ethyl-4-bromobutyrate
1H-NMR (200 MHz, DMSO-d6 δ) 1.19 (t, J = 7.1 Hz, 3H, H1), 2.00 (dt,
J = 6.6 Hz, J = 7.3 Hz, 2H, H5), 2.44 (t, J = 7.3 Hz, 2H, H4), 3.55 (t, J = 6.6 Hz,
2H, H6), 4.01 (quad., J = 7.1 Hz, 2H, H2).
13C-NMR (200 MHz, DMSO-d6 δ) 14.04 (C1), 27.68 (C5), 31.99 (C4),
33.89 (C6), 59.93 (C2), 171.92 (C3).
124


Appendix B
pH calculations
Appendix B ALTHERAS
B.1 Lactic acid solution
For a weak acid, the acid dissociation constant is expressed as:
Ka =
[A−] [H3O+]
[AH] (B.1)
where
[A−] Concentration of conjugated base ions
[H3O+] Concentration of [H3O+] ions
[AH] Concentration of undissociated acid molecules
As the solution stays neutral [H3O+] = [A−]
If CA0 is the initial concentration of lactic acid then [A−] = CA0 – [H3O+]
Finally, by replacing in the Ka equation:
[H3O+]2 +Ka [H3O+]−Ka CA0 = 0 (B.2)
By solving this equation:
[H3O+] =
1
2
(
−Ka +
√
K2a + 4 Ka CA0
)
(B.3)
With CA0 =
m
Mw V
(B.4)
where
m The mass of lactic acid in solution
Mw The molecular weight of lactic acid
V The volume of the solution
Finally, as pH = – log[H3O+] so:
pH = −log
(
1
2
(
−10−pKa +
√
10−2 pKa + 4 m 10
−pKa
Mw V
))
(B.5)
Using the same equation, the uncertainties on the expected value for the pH
are calculated using the relation:
δpH =
√∣∣∣∣ ∂pH∂pKa
∣∣∣∣2 |δpKa|2 + ∣∣∣∣∂pH∂m
∣∣∣∣2 |δm|2 + ∣∣∣∣∂pH∂V
∣∣∣∣2 |δV |2
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B.2 Ammonia solution
For a weak base, the acid dissociation constant is expressed as:
Kb =
[BH+] [HO−]
[B] (B.6)
where
[BH+] Concentration of conjugated acid ions
[HO−] Concentration of [HO−] ions
[B] Concentration of undissociated basic molecules
As the solution stays neutral [HO−] = [BH+]. If CB0 is the initial concen-
tration of ammmonium hydroxide then [B] = CB0 – [HO−]
Finally, by replacing in the Kb equation:
[HO−]2 +Kb [HO−]−Kb CB0 = 0 (B.7)
By solving this equation:
[HO−] = 12
(
−Kb +
√
K2b + 4 Kb CB0
)
(B.8)
With CB0 =
C0 V0
VB0
(B.9)
where
C0 The concentration of commercial ammonia solution
V0 The volume of initial ammonia solution transfered
VB0 The volume of the final solution
Finally, as pH = 14 – log[HO−] so:
pH = 14− log
1
2
−10−pKb +
√
10−2 pKb + 4 C0 V0 10
−pKb
VB0
 (B.10)
Using the same equation, the uncertainties on the expected value for the pH
are calculated using the relation:
δpH =
√∣∣∣∣ ∂pH∂pKb
∣∣∣∣2 |δpKb|2 + ∣∣∣∣∂pH∂C0
∣∣∣∣2 |δC0|2 + ∣∣∣∣∂pH∂V0
∣∣∣∣2 |δV0|2 + ∣∣∣∣ ∂pH∂VB0
∣∣∣∣2 |δVB0|2
129

Appendix C
Nomenclature
Appendix C ALTHERAS
The possibilities that are resulting from the creation of the ATTS for poly-
therapies and chronotherapies require the introduction of a tool able to describe
in a simple way the structure of the mS. Considering the amount of parameters
involved a nomenclature is proposed to characterize theChipM produced using
the POMAP.
C.1 Non-modified ChipM
The complete dissolution of chitosan is dependent on the acid concentration.
Therefore, the full dissolution of chitosan is considered as total when all GlcNH
units are protonated. As a consequence, the concentration of acid is directly in
relation with the amount of amine moieties on chitosan. For this reason, the
mass of chitosan that is possible to dissolve in a X%(v:v) solution of lactic acid
(LA) is given by the relation:
mchitosan =
mLA Mwchitosan
MwLA DDA DP
(C.1)
With DP = Mwchitosan −MwH2O
DDA MwGlcNH + (1−DDA) MwGlcNAc −MwH2O
(C.2)
Mwchitosan ∈ [190,000;310,000] g·mol−1 and DDA = 0.818
Lactic acid concentration mchitosan(g)
mchitosan
retained (g)
0.25%(w:v) 27.7538 mM [0.57277;0.57279] 0.5 g
0.50%(w:v) 55.5075 mM [1.14555;1.14559] 1.0 g
0.75%(w:v) 83.2613 mM [1.71832;1.71838] 1.5 g
1.00%(w:v) 111.0150 mM [2.29109;2.29118] 2.0 g
1.25%(w:v) 138.7688 mM [2.86387;2.86397] 2.5 g
1.50%(w:v) 166.5225 mM [3.43664;3.43677] 3.0 g
1.75%(w:v) 194.2763 mM [4.00941;4.00956] 3.5 g
2.00%(w:v) 222.0300 mM [4.58219;4.58236] 4.0 g
2.25%(w:v) 249.7838 mM [5.15496;5.15515] 4.5 g
2.50%(w:v) 277.5376 mM [5.72773;5.72794] 5.0 g
The nomenclature (Figure C.1) for non-modifiedChipM finally consists to
describe each matrix by three parameters which are the concentration in chi-
tosan, the concentration in acid and the cooling rate used to produce it. As
exposed above, the dissolution of the chitosan depends on the concentration in
acid. This explains the “stairs” shape of the nomenclature. In this nomencla-
ture, the concentration of lactic acid used to dissolve the polymer is described
by the green scale.
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Figure C.1: Nomenclature for the non-modifiedChipM
The blue part represents the chitosan concentration (from 0.5 to 5.0 g per
100 ml of acid solution) and the cooling rate imposed by the POMAP (from 0.1
to 1.0 ℃·min−1). Finally the intersection of a blue column with a green level
allows a perfect description of theChipM. The matrix is finally characterized
by the number of the column and the number of the level.
A matrix is written
(
W
acid|X
)·ChipM, with W the level on green scale, X the
column and the name of the acid.
C.2 Modified ChipM
The nomenclature suggested allows a precise description of a matrix after its
modification. As presented in Chapter 4, these modifications can consist out of
several designs.
C.2.1 Conventions of writing
C.2.1.1 Major rules
• Primary coupling: The agents Y covalently bound in a permanent way
are written to the right. In case of several primary couplings on the
same ChipM they are separated by a vertical bar and the order is not
considered ;
Example:
(
W
acid|X
)·ChipM·Y or ( Wacid|X)·ChipM·Y1|Y2
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• Secondary coupling: The agents Z covalently bound in a non permanent
way are written to the right between parentheses (Z). In case of several
secondary couplings on the sameChipM they are separated by a vertical
bar and the order is not considered ;
Example:
(
W
acid|X
)·ChipM·(Z) or ( Wacid|X)·ChipM·(Z1|Z2)
• Diffusion media: Considering the possibility to use a dM loaded with
actives, for passive release, the loading is written to the right between
braces {lo}. In case of multi-loading on the same dM, they are separated
by a vertical bar and the order is not considered ;
Example:
(
W
acid|X
)·ChipM·{lo} or ( Wacid|X)·ChipM·{lo1|lo2}
• Doped matrix: The ChipM structure can also be doped during its pro-
duction by incorporating an agent in the initial chitosan solution. This
doping agent can be used to modify the physicochemical characteristics of
the ChipM but it can also be released. In that case the doped ChipM
acts as a passive delivery system. The doping agent is written to the left
between parenthesis (do). In case of multi-doping on the same ChipM,
they are separated by a vertical bar and the order is not considered ;
Example: (do)·( Wacid|X)·ChipM or (do1|do2)·( Wacid|X)·ChipM
C.2.1.2 Minor rules
• If the agent is an active molecule, this is specified by the addition of the
letter A as subscript ;
Example:
(
W
acid|X
)·ChipM·(ZA), ( Wacid|X)·ChipM·{loA}
and (doA)·
(
W
acid|X
)·ChipM
• If the agent is a particle, this is specified by the addition of the letter P
as subscript ;
Example:
(
W
acid|X
)·ChipM·(ZP ), ( Wacid|X)·ChipM·{loP }
and (doP )·
(
W
acid|X
)·ChipM
• If the agent is a permeation enhancer, this is specified by the addition of
the letter E as subscript ;
Example:
(
W
acid|X
)·ChipM·(ZE), ( Wacid|X)·ChipM·{loE}
and (doE)·
(
W
acid|X
)·ChipM
• If the agent does not have any particular role, it is only described by the
major rules.
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C.2.2 Rules of priority
• A primary coupling has priority on a secondary coupling ;
Example:
(
W
acid|X
)·ChipM·Y·(Z), ( Wacid|X)·ChipM·Y1|Y2·(Z)(
W
acid|X
)·ChipM·Y·(Z1|Z2)
and
(
W
acid|X
)·ChipM·Y1|Y2·(Z1|Z2)
• A secondary coupling has priority on a loaded dM ;
Example:
(
W
acid|X
)·ChipM·(Z)·{lo},(
W
acid|X
)·ChipM·(Z1|Z2)·{lo}, ( Wacid|X)·ChipM·(Z)·{lo1|lo2}
and
(
W
acid|X
)·ChipM·Y·(Z)·{lo}
C.3 Examples
Several examples, used in this project or not are presented below.
C.3.1 Primary coupling
C.3.1.1 Acetylation as primary coupling
H
N
O
Figure C.2: Primary coupling example with acetylation(
W
acid|X
)
·ChipM·OAc
C.3.1.2 PL1 as primary coupling
H
N
O
O
O
NH2
NO2
Figure C.3: Primary coupling example with PL1(
W
acid|X
)
·ChipM·PL1
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C.3.1.3 PL2 as primary coupling
H
N
O
O
O
OH
NO2
Figure C.4: Primary coupling example with PL2(
W
acid|X
)
·ChipM·PL2
C.3.2 Secondary coupling
C.3.2.1 Amide bound on PL1
This coupling is obtained by an amide bound formation on PL1 using a car-
boxylic acid. The released molecule is an amide.
H
N
O
O
O
N
H
O
R
NO2
Figure C.5: Secondary coupling example on PL1(
W
acid|X
)
·ChipM·PL1·(RCOOH)
• Amide bound with PLGA nanoparticles: The use of drug loaded PLGA
nanoparticles (PLGAP ), allows the release of molecules without functional
group but also to reach a higher drug loading. In that case the reaction has
to be conducted in water to avoid PLGA dissolution. The amide PLGA
is released.
H
N
O
O
O
N
H
O
PLGA
NO2
Figure C.6: Secondary coupling example on PL1 with a PLGA nanoparticle(
W
acid|X
)
·ChipM·PL1·(PLGAP )
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• Amide bound with amino acid and nanoparticles: To avoid the release of
lactic amide or glycolic amide by direct coupling on PL1, a possibility is
to introduce an amino-acid between the photolinker and the nanoparticle.
Since the toxicity of several amino amide is known to be almost inexistent,
this allows the release of a drug without any disadvantages induced by the
presence of amides.
H
N
O
O
O
N
H
O
A
A
H
N
O
PLGA
NO2
Figure C.7: Secondary coupling example on PL1 with a PLGA nanoparticle
and an amino acid(
W
acid|X
)
·ChipM·PL1·(AA|PLGAP )
C.3.2.2 Ester bound on PL2
Contrary to PL1, the photolinker PL2 makes the release of carboxylic acids
possible.
H
N
O
O
O
O
O
R
NO2
Figure C.8: Secondary coupling example on PL2(
W
acid|X
)
·ChipM·PL2·(RCOOH)
• Ester bound with amino acid and nanoparticles: As for PL1, the intro-
duction of PLGA nanoparticles is possible, in that case without release of
amides.
H
N
O
O
O
O
O
A
A
H
N
O
PLGA
NO2
Figure C.9: Secondary coupling example on PL2 with a PLGA nanoparticle
and an amino acid(
W
acid|X
)
·ChipM·PL2·(AA|PLGAP )
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C.3.2.3 Carbonate bound on PL2
The introduction of p-NPCF, which is a good leaving group, is a good way to
obtain carbonates and carbamate bounds on PL2.
• Carbonate on PL2: Upon UV illumination, the carbonate PL2 releases an
alcohol and CO2.
H
N
O
O
O
O
O
O
R
NO2
Figure C.10: Secondary coupling example on PL2 with an alcohol(
W
acid|X
)
·ChipM·PL2·(ROH)
• Carbamate on PL2: Upon UV illumination, the carbamate PL2 releases
an amine and CO2.
H
N
O
O
O
O
O
N
H
R
NO2
Figure C.11: Secondary coupling example on PL2 with an amine(
W
acid|X
)
·ChipM·PL2·(RNH2)
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